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Abstract 5 
Cephalotaxus alkaloids represent a family of plant secondary metabolites known for 60 years. 
Significant activity against leukemia in mice was demonstrated for extracts of Cephalotaxus. 
Cephalotaxine (CET) (1), the major alkaloid of this series was isolated from Cephalotaxus 
species by Paudler in 1963. The subsequent discovery of promising antitumor activity among 
new Cephalotaxus derivatives reported by Chinese, Japanese and American teams triggered 10 
extensive structure elucidation and biological studies in this family. The structural feature of this 
cephalotaxane family relies mainly on its tetracyclic alkaloid backbone, which comprises an 
azaspiranic 1-azaspiro[4.4]nonane unit (rings C and D) and a benzazepine ring system (rings A 
and B) which is linked by its C3 alcohol function to a chiral oxygenated side chain by a 
carboxylic function alpha to a tetrasubstituted carbon center. The botanical distribution of these 15 
alkaloids is limited to the Cephalotaxus genus (Cephalotaxaceae). The scope of biological 
activities of the Cephalotaxus alkaloids is mainly centered on the antileukemic activity of 
homoharringtonine (HHT) (2), which in particular demonstrated marked benefits in the treatment 
of orphan myeloid leukemia and was marketed as soon as 2009 by EMA (European Medicine 
Agency) and was approved by US Food and Drug Administration (FDA) in 2012. Its exact 20 
mechanism of action was partly elucidated and it was early recognized that HHT (2) inhibited 
protein synthesis at the level of the ribosome machinery. Interestingly, after a latency period of 2 
decades, the topic of Cephalotaxus alkaloids reemerged as a prolific source of new natural 
structures. To date, more than 70 compounds have been identified and characterized. Synthetic 
studies also regained attention during the two past decades, and numerous methodologies were 25 
developed to access the first semisynthetic HHT (ssHHT) (2) of high purity suitable for clinical 
studies, and then high grade enantiomerically pure CET (1), HHT (2) and analogs. 
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I. Introduction 
This contribution is an updated and expanded version of the two previous chapters 
published in this series in 19841 and 1998.2 Other reviews focused on the structure and synthesis 
of these compounds,3,4,5,6 and several reviews are available that cover the structure–activity 5 
relationships, biological and clinical properties of these alkaloids.7,8,9,10,11,12,13,14,15,16,17,18,19 The 
literature is reviewed from the last update in this series which was covering the field till mid-
1997, to early 2016. Because they usually exist under the form of unique enantiomer, we 
numbered the natural products by an arabical digit irrespective to their optical rotation sign, e.g. 
cephalotaxine (CET) (1), their antipode by ent-digit e.g. ent-cephalotaxine ent-(1), and the 10 
corresponding racemic compound usually obtained by chemical synthesis rac-digit, e.g. rac-
cephalotaxine rac-(1). In the asymmetric synthesis section, we have precised the sign of the 
optical rotation, e.g. CET (–)-(1), ent-CET (+)-(1) and rac- CET (±)-(1). 
For more than fifty years, chemists have studied the extraction, structure determination, 
biogenesis and synthesis of CET (1) (Figure 2), the major alkaloid of this series, and related 15 
alkaloids, because of the reported biological activity of its natural esters 2–5, in view of their 
therapeutically use in the treatment of leukemia. Homoharringtonine (HHT) (2) and 
harringtonine (HT) (3), or mixtures of both, have been used in traditional Chinese medicine 
(TCM) since the 1970s to treat a variety of malignancies. HHT (2) being the easiest to purify and 
the most abundant in the plant was selected by the National Cancer Institute (NCI) for clinical 20 
development. HHT (2), also known as omacetaxine®, a simple ester of CET (1), probably holds 
the record for the longest time to reach the market20 after having experienced increasing interest 
since its first use in TCM, and efforts by pharmaceutical companies for its development as an 
antileukemic agent. Despite its clinical efficacy, natural HHT (2) was not recorded until now, 
simply because normal extract formulations have raised several unresolved problems, such as the 25 
reproduction of a constant product from defined extraction procedure, the purity profile, the main 
source of the raw material in China and biodiversity conservation issues. The Cephalotaxus 
shrubs with extremely slow growth are mostly protected and endangered species. Moreover, 
CET (1) and its active esters are present in small quantities in the plant (roots, bark, heartwood 
and leaves), which hardly makes possible to exploit it in order to obtain HHT (2) or its related 30 
esters. Semisynthetic HHT (ssHHT) (2) (Myelostat®, Ceflatonin® or Omacetaxine 
mepesuccinate) is manufactured by a semi-synthetic process developed by Robin from naturally 
occurring alkaloid (–)-CET (1) extracted from the dry leaves of C. harringtonia, and a synthetic 
precursor side chain.21 Although HHT (2) was investigated for the treatment of chronic myeloid 
leukemia (CML) in the 1990s with good results, the advent of Imatinib mesylate, a BCR-ABL1 35 
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tyrosine kinase inhibitor (TKI) at that time delayed the interest for HHT (2). However, de novo 
or acquired resistance to TKIs22 renewed the interest for this alternative first-in-class simple 
natural ester of CET (1). HHT (2) is currently approved in Europe and in the USA, due to its 
reported activity in patients with chronic myelogenous leukemia (CML) resistant to currently 
available TKIs. As a result, on 2nd September 2004, orphan designation (EU/3/04/224) was 5 
granted by the EU for omacetaxine mepesuccinate® (INN, trade name Synribo) 
/homoharringtonine (HHT) (2) for the treatment of chronic myeloid leukemia to Stragen France 
SAS, France, for the treatment of chronic myeloid leukemia. Exploitation rights were 
transferred to ChemGenex Europe SAS, France, in January 2009 and subsequently to Teva 
Pharma GmbH, Germany, in December 2012. Due to their different mechanisms of action, 10 
combinations with TKIs represent attractive treatment options. Recently, on 26th October 2012, 
HHT (2), Synribo® (formerly Ceflatonin, Omapro), received an accelerated approval by the U.S. 
Food and Drug Administration (FDA) for adult patients with chronic-phase or accelerated-phase 
CML with resistance or intolerance to two or more TKIs. The U.S. FDA has granted full 
approval to HHT (2) (drug substance international nonproprietary name (INN) omacetaxine 15 
mepesuccinate, Synribo®) for injection, based on the final analysis of two phase II trials 
evaluating the efficacy and tolerability data of omacetaxine in 2014. This renewed interest for 
isolation, characterisation, biological evaluation and total synthesis of cephalotaxus alkaloids 
and analogs to suppress the dependance on natural source supply. 
2. Natural Occurrence, Isolation and Structural Assignment 20 
As early as 1954, Wall brought to light the presence of alkaloids in plants of the genus 
Cephalotaxus,23  the only genus of the Cephalotaxaceae family composed of eleven species of 
evergreen small and only slowly growing conifers which are mostly indigenous to China (Figure 
1). The first alkaloid characterized from C. harringtonia var. drupacea (C. drupacea) and C. 
fortunei was named cephalotaxine by Paudler in 196324 and its original benzazepine nucleus 25 
fused to an azaspirononane unit established by Powell et al. (Figure 2).25 
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Figure 1. Scientific classification of Cephalotaxus genus and picture (from A. Barra, Wikimedia 
Commons) of the fruits and leaves of C. harringtonia var drupacea. 
 
Although its biological activity and partial structure are known since 1959,26 the elucidation of 5 
the structure and antitumor activity of natural harringtonine (HT) (3) (Figure 2) isolated from 
Cephalotaxus harringtonia var. drupacea against L1210 and P388 leukemia in mice (1 mg/kg) 
in 196925 stimulated the continuous search for active compounds and particularly for alkaloids 
from the Cephalotaxus genus. Apart from the cephalotaxine series focused in this chapter, the 
other alkaloid part in Cephalotaxus species belongs to the class of homoerythrinane alkaloids, 10 
isolated as minor compounds with the exception of C. wilsoniana. Biogenesis of CET (1) 
postulated by Parry in 1977 showed a common origin for these alkaloids.1,2,27 
 
Figure 2. Cephalotaxine (1) and its natural esters (2)–(5) early characterized in C. harringtonia 
var. drupacea  15 
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Cephalotaxanes (6) is the generic name for the particular alkaloids of the 
Cephalotaxaceae family which have a general formula derived from the cephalotaxane skeleton 
with either 1 or 2 units covalently linked forming dimers having two identical or different units 
(Figure 3). Cephalotaxanes (6) include neutral compounds or salts having this basic skeleton in 5 
common, and may contain various oxygenated substituents (aliphatic ethers or aromatic units, 
free or esterified alcohols, substituted or free enols, phenol and others). Cephalotaxanes include 
cephalotaxines characterized by a free alcohol function on ring D (R = H), and harringtonines 
where the 3-OH group is esterified (R ≠ H). Isolation of cephalotaxanes and homoerythrinane 
alkaloids [skeleton (7)] from the same plant suggested that they might be formed through similar 10 
biogenetic routes.1,2 Hainanensine (8) is a structurally unique Cephalotaxus alkaloid devoid of 
optical activity and lacking the spiranic tetrasubstituted carbon center. It was isolated from C. 
hainanensis and C. fortunei (Figure 3) and displays a type of single rearranged cephalotaxine 
skeleton.28 
 15 
 
Figure 3. Cephalotaxanes (6), the skeleton 7 of minor homoerythrinane alkaloids and the 
structurally unique Cephalotaxus alkaloid hainanensine (8). 
 
Until 1997, thirty six compounds related to the cephalotaxine series (Tables 1 and 2), were 20 
described, of which twenty three are natural esters and one is dimeric.  
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CET (1) and HHT (2) were also isolated conventionally from fruits, leaves and branches 
of Cephalotaxus sinensis.29 Among the alkaloids derived from CET (1), compounds possess 
different D rings such as cephalotaxinone (10), demethylcephalotaxine (11), isocephalotaxinone 
(13) and ring C such as cephalotaxinamide (18). Oxygenated compounds with modifications on 
their B ring as 11-hydroxycephalotaxine (14) and 4-hydroxycephalotaxine (15), or compounds 5 
having an oxygen bridge between the rings B and D like drupacine (16) were also described 
(Figure 4).30,31,32 11-Hydroxycephalotaxine (14) was converted to drupacine (16) in acidic 
medium.31 Among the minor alkaloids isolated from the bark of Cephalotaxus hainanensis Li (in 
addition to eleven known alkaloids), cephalotaxine analogs were identified as cephalotaxinone 
(10), cephalotaxinamide (18) and demethylneodrupacine (17) which possesses an ether bridge 10 
between C11 and C3, while drupracine (16) exhibits an ether bridge between C11 and C2. The 
structure of desmethylcephalotaxinone (12), isolated from Cephalotaxus harringtonia (Forbes) 
K. Koch var. harringtonia cv. Fastigiata, was determined by semisynthesis from CET (1) via 
oxidation to cephalotaxinone (10) and cleavage of the enol ether thus confirming desmethylCET 
(12) as a natural metabolite and biosynthesic intermediate.33  15 
Repeated chromatography of an alkaloidal fraction of the ethanolic extract of 
Cephalotaxus fortunei Hook f.34 afforded as minor component (+)-4-hydroxycephalotaxine (+)-
(15) recently also identified in C. koreana Nakai.35 Epicephalotaxine (9) is another minor 
metabolite of C. fortunei Hook f. accompanied by CET (1) (50-54% of the total alkaloids), 
cephalotaxinone (10), (+)-acetylCET (+)-(26), demethylCET (11), HT (3) and HHT (2).36 20 
Molecules coupled with side chains bearing an ester function as in nordeoxyharringtonine 
(nordeoxyHT) (21), homodeoxyharringtonine (homodeoxyHT or deoxyHHT) (22) and 
bishomodeoxyharringtonine (bishomodeoxyHT) (23) are found among harringtonines (Figure 
5).37  
Including esters 2–5, these compounds are esters of CET (1) having its polycyclic core 25 
coupled to different side chains deriving from (R)-citramalic acid. Although occurence of 
enantiomeric pairs in the same family of plants is unusual,38 acetylcephalotaxine (acetylCET) 
(26) was reported under both enantiomeric forms. (–)-AcetylCET (–)-(26) was obtained by 
semisynthesis through acetylation of natural CET (–)-(1)24 and was isolated from C. fortunei30 
and C. wilsoniana.39,40 30 
 13 
 
The opposite enantiomer (+)-acetylCET (+)-(26) was isolated in C. fortunei41 and C. 
hainanensis.42 Although an error cannot be excluded in literature data, these findings need to be 
confirmed since this natural product (+)-26 is the only one portraiting an opposite absolute 5 
configuration (AC) of alkaloid core. 
Anhydroharringtonine (20) bearing an additional heterocycle in the side chain is the only natural 
ester of this type.43 It induced 98% growth inhibition of P388 leukemia cell lines at 1 µg/mL, a 
level comparable to that of deoxyHT (5). There are also molecules coupled with side chains 
carrying a free acid group (Figure 5): 5'-des-O-methylHT (30) (harringtonic acid), (2’R,3'S)-3’-10 
hydroxy-5'-des-O-methylHT (28) (cephalozemic acid C), 5'-des-O-methylHHT (31) 
(homoharringtonic acid, also identified as a metabolite of HHT (2) in rats and rabbits) and 5'-
des-O-methylisoHT (27) (isoharringtonic acid).1,2 Others possess an ester function and an 
 14 
aromatic ring, as in homoneoHT (24) and (2’R,3'S)-hydroxyneoHT (25).44 Some of these esters 
deliver biological activities comparable to those of the first four isolated esters 2–5 but they are 
available in much lower quantities in the plant. The first dimeric Cephalotaxus alkaloid, 
cephalotaxidine (37), was isolated from C. harringtonia var. drupacea (C. drupacea) in 1996.45 
It is a dimer of HHT (2) and homoharringtonamide (32) with an IC50 of 1.8 µg/mL against P-388 5 
murine leukemic cell lines. Drupangtonine (33),46 was the most active (IC50 7 nM against P-388 
murine leukemic cell lines) of the four esters of oxygenated cephalotaxine analogs, 11α-
hydroxy-homodeoxyHT (34), 11β-hydroxyhomodeoxyHT (35) and 11β-hydroxydeoxyHT (36) 
(IC50 0.38, 0.33 and 0.17µg/mL respectively against P-388 murine leukemic cell lines) identified 
from C. harringtonia var. drupacea (Figure 6).47  10 
 
 
Figure 4. Oxydized cephalotaxines 
 15 
Figure 5. Natural esters of cephalotaxine and cephalotaxinamide 
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Figure 6 Natural esters of oxygenated cephalotaxines 
 
Since the last reviews in this series,1,2 more than thirty Cephalotaxus alkaloids have been isolated 
from various Cephalotaxus sp. These new alkaloids include the following compounds. 5 
2.1 Cephalotaxine and Related Alkaloids 
N-oxides of cephalotaxine, CET α N-oxide (38), CET β N-oxide (39) and 11β-
hydroxycephalotaxine β N-oxide (40), together with isocephalotaxine (41) were identified and 
characterized in the ethyl acetate extract of C. fortunei fruits by Jossang et al. in 2001 (Figure 
7).48 Although it was described as a synthetic compound earlier,49 the relative configuration of 10 
isocephalotaxine (41) isolated during this work remains unknown due to the lack of NOESY 
correlations. These alkaloids exhibited low cytotoxicity against nasopharynx KB cells with IC50 
values of 30, 14, 31 and 15 µg/mL, respectively. ACs of cephalezomines G (42) and H (43) 
described by Kobayashi and Morita50 from the leaves of C. harringtonia var. harringtonia were 
determined by circular dichroism (CD) as 2S,3R for cephalezomine G (42) and 2R,3R for 15 
cephalezomine H (43). However, the structure of cephalezomine H (43), initially assigned as a 
trans diol was revised to a syn-β,β-diol after total synthesis (Figure 7).51 Some uncertainty 
remained, however, due to the divergent optical rotations of the synthetic and the natural 
compounds. 
  20 
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Figure 7. New N-oxides and ring D analogs of cephalotaxine 
 
A new stereoisomer (44) of desmethylcephalotaxinone (12) has been isolated from the leaves 
and heartwood of Formosan Cephalotaxus wilsoniana (Figure 8).52 Although the UV, 1H NMR, 5 
and []23D of compound 44 were similar to those of natural desmethylcephalotaxinone (12), C1 
to C7 and C10 signals in the 13C NMR spectrum differ from the one of the synthetic sample of 
12.100 Evidence that compound 44 was a stereoisomer of desmethylcephalotaxinone (12) was 
also based on H1 and H6 cross-peak in the NOESY correlation chart of 44. While this 
correlation seems doubtful, since only one stereogenic carbon center is present in structures 12 10 
and 44, these findings imply that the second stereogenic center is the nitrogen atom that lost its 
fast inversion properties, as observed in the X-ray studies showing the rigid structure of CET 
(1).53 Compound 44 showed no cytotoxic activity against the Hep G2, MCF-7, Hep 3B, and HT-
29 human cancer cell lines.  
A phytochemical investigation of the branches and leaves of C. lanceolata, a Cephalotaxus 15 
species native to Yunnan Province, China, resulted in the isolation of three new Cephalotaxus 
alkaloids, cephalancetines A (45) and B (46), and unsymmetrical dimer cephalancetine D (47) 
together with known cephalancetine C (48) isolated for the first time from this plant, along with 
nine other known alkaloids (Figure 8).54 The structure of cephalancetine C (48) was 
unambiguously confirmed by single-crystal X-ray diffraction as consisting of cephalotaxine (1) 20 
linked at C8 to C7 (C26) of cephalotaxinamide (18) thus establishing its AC as 
(3S,4S,5R,8S,22S,23S,24R,26S). Cephalancetine D (47) is a dimer consisting of drupacine (16) 
linked at C8 to C7 (C26) of cephalotaxinamide (18). Cephalancetine C (48) was identical to the 
saponification product of bis-cephalezomines (see Figure 12) with LiOH.55 
 18 
 
 
Figure 8 Desmethylcephalotaxinone stereoisomer and cephalancetines A–D 
 
All these isolated alkaloids were tested for their cytotoxicities against four human tumor cell 5 
lines, A549, HCT116, SK-BR-3, and HepG2 that evidenced that HT (3) and HHT (2) can 
strongly inhibit the proliferation of these human tumor cell lines as well, however with limited 
potency against SK-BR-3 cells (Table 3).54  
 
Harringtonine (3) showed remarkable cytotoxicity against A549, HCT116, and HepG2 cell lines 10 
with IC50 values of 0.15, 0.054, and 0.38 µg/ml, respectively. HHT (2) also exhibited potent 
cytotoxicity against A549, HCT116, and HepG2 cell lines with IC50 values of 0.085, 0.001 and 
0.087 µg/ml, respectively, 85 times stronger than that of doxorubicin against HCT116 cell line. 
Comparing the relationship between the structures with their cytotoxicities, the ester side chains 
 19 
at C3 of the cephalotaxine skeleton seem to play the most prominent role in the cytotoxic activity 
of these alkaloids. 
Four new cephalotaxus alkaloids, cephalotines A–D (49)–(52) were isolated from the 
leaves and twigs of Cephalotaxus lanceolata and C. fortunei var. alpina (Yunnan province, P.R. 
China) along with 24 known alkaloids (Figure 9). None of these compounds showed significant 5 
activity against HeLa, SGC-7901 gastric cancer and A-549 lung cancer cell lines (IC50 >20 
µM).56  
 
 
Figure 9 Cephalotines A-D 10 
 
2.2 Natural Cephalotaxus esters 
In 2000, Kobayashi et al. isolated from the leaves of Cephalotaxus harringtonia var. nana new 
cytotoxic alkaloids, cephalezomines A (53) and B (54) which are esters of drupacine (16), as 
well as cephalezomines C–F (55)–(58) which are esters of CET (1) (Figure 10).57 These new 15 
compounds were found together with seven known alkaloid esters, HT (3), isoHT (4), deoxyHT 
(5), homodeoxyHT (22), CET (1), and related cephalotaxine alkaloids, demethylCET (11),30 
11-hydroxyCET (14) and drupacine (16). Their structure and stereochemistry were elucidated 
by spectroscopic data, circular dichroism and X-ray diffraction analysis.  
Among the new Cephalotaxus alkaloids possessing a cephalotaxine type backbone with various 20 
side chains at C3, cephalezomine D (56) is the first one with (2'R,3'R) AC. In this study57 the 
team of Kobayashi also described the cytotoxicity of these alkaloids against L1210 and KB cell 
lines (Table 4). Two years later, Kobayashi and Morita reported the isolation of five new 
alkaloids, cephalezomines G, H and J–L from the leaves of C. harringtonia var. nana (Sapporo, 
Japan). Among them, cephalezomines K (59) and L (60) are esters of CET (1) epimers at C4” 25 
(Figure 10).58 
 
 20 
 
Figure 10. Cephalozemines A–F and K–L and their yield from the natural sources in brakets 
 21 
 
In 2010, Morita et al. characterized from the leaves of C. harringtonia forma fastigiata a new 
alkaloid, cephastigiamide A (61),59 []20D –55 (c 0.1, MeOH), along with CET (1), 
cephalotaxinamide (18), bis-cephalezomine A (65), homodeoxyHT (22), and two HHT N-oxides, 5 
HHT  N-oxide (62) and HHT β N-oxide (63), previously prepared by Takano60,61 for SAR 
studies (Figure 11). HHT (2) and HT (3) showed pronounced antiplasmodial activity against 
Plasmodium falciparum 3D7 but to a lesser extent against Leishmania major (Table 5), while 
deoxyHT (5) and homodeoxyHT (22) were active in the two tests. 
HHT  N-oxide (62) and HHT β N-oxide (63) reported for the first time as natural products, did 10 
not display any antileishmanial or cytotoxic activity against A549 cell line, despite the presence 
an esterified 3-OH function in their structures (Table 5). Structure-activity relationship directed 
toward antiplasmodial activity of isolated Cephalotaxus alkaloids was also discussed. 
Cephalezomine J (64) from the leaves of Cephalotaxus harringtonia var. nana (Figure 11) is the 
unique cephalotaxine conjugate with a sugar type side chain (D-glucose).50 Although the data 15 
collected in this study are cytotoxicity values (Table 5), a selectivity index was calculated to rate 
this effect on human versus parasitic cell lines. In all the cases, the cytotoxicity was greater 
against parasites, rather on tumor cells (SI > 1). 
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Figure 11. Oxygenated Cephalotaxus esters and Cephalozemine J 
 5 
In 2009, Kobayashi et al isolated five new dimeric alkaloids from C. harringtonia var. 
nana, especially heterodimers, named bis-cephalezomines A–E (65)–(69) (Figure 12).55 The 
alkaloids that constitute the dimers [HHT (2), HT (3), deoxyHT (5) and cephalezomine A (53)] 
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showed potent cytotoxic activity whereas dimers were far less active against L1210 murine 
lymphoma cells, with IC50 values in the range of 1.9 to 3.7 µg/mL. 
 
 
Figure 12. Dimeric Cephalotaxus esters 5 
 
2.3 Other alkaloids 
The new alkaloid cephalocyclidin A (72) with an unprecedented polycyclic fused rearranged 
skeleton derived from CET (1) and six contiguous asymmetric centers was isolated from fruits of 
Cephalotaxus harringtonia var. nana.62 ACs at C2 and C3 were assigned by the exciton chirality 10 
method as 2R and 3S, respectively, indicating 1R,2R,3S,4S,5R,11S configuration, compatible 
with the absolute stereochemistry of the hydrochloride of CET (1) deduced through the Flack 
parameter of 0.01(5), in the X-ray analysis. It could be derived biogenetically by formation of 
the C1–C11 link of 71 by an intramolecular aldol reaction of the putative intermediate 11-
oxodemethylcephalotaxine (70) followed by reduction (Scheme 1). The in vitro cytotoxicity 15 
(IC50) of cephalocyclidin A (72) against the L1210 mouse lymphoma and human epidermoid 
carcinoma cells KB is 0.85 and 0.80 µg/mL respectively. 
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Scheme 1. Proposed biosynthetic pathway to cephalocyclidine A 
 
2.4 Production and purification studies 
The proportion of the four major natural esters 2–5 with antitumor activity is between 0.7% in 5 
the needles of C. fortunei and 36% in the roots of C. harringtonia var. harringtonia of the total 
amount of alkaloids. This plant is the best natural source for these four compounds of 
pharmacological interest. At present, the plants of the genus Cephalotaxus are endangered 
species and face the threat of extinction. Only the renewable parts of the plant are used for the 
extraction of alkaloids. For example, the use of modern methods of extraction provides up to 2 10 
kg of pure CET (1) from a ton of dry leaves, that is 0.2% of dry matter. Robin et al. studied a 
method of preparation of HHT (2) by semi-synthesis from natural CET (1) by attachment of the 
side chain (see section 3). Purification provided a drug whose purity was 99.8% against 98.5% 
for NCI products and 95-97% for products of Chinese origin (Table 7).63 For example, 550 g of 
HHT (2) were injected into a preparative HPLC system (diameter 45 cm, height 1 m containing 15 
48 kg of ODS stationary phase). The elution was performed using a gradient of buffered solution 
of pH 3 methanol-water as mobile phase (flow rate 540 L/h, 1200 psi). The collected fractions 
(20 to 50 L) were separated by UV detection and analyzed by HPLC. After eliminating fractions 
with about 0.5% of the total content of HHT (2), fractions suitable for specification (purity> 
99.8%) were combined. HPLC analysis of the organic phase after HHT recovery (basified to pH 20 
8.5 and extracted with dichloromethane) showed a level of impurities less than 0.5%. HHT (2) 
(210 g) was then recrystallized by dissolution in 240 mL of methanol at 30 °C, filtration at 0.25 
microns for sterilization, then deionized water (2.4 L) was added and methanol was distilled off. 
The aqueous solution of HHT (2) DS (quality "drug substance") or "drug substance" quality (DS) 
was held in a decontaminated rotary evaporator until the appearance of white crystals of pure 25 
HHT (2). After filtration and drying under vacuum at 60 °C for 2 days, 88% overall yield (OY) 
of HHT (2) was obtained when compared to its potential content in the semisynthetic gross HHT 
(2). This corresponds to a clinical batch allowing for the preparation of 40.000 therapeutic 
dosage units containing 5 mg to less than 0.03% of impurities.63 
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Numerous methods were described for the extraction and purification of cephalotaxine, its 
natural esters and related analogs. Extraction of CET (1) and HHT (2) with 90% ethanol under 
refluxing conditions allowed for the isolation from fruits, leaves, or branches of Cephalotaxus 
sinensis after acid base treatment and chromatographic purification on alumina.64 
High speed countercurrent chromatography (HSCC), a form of liquid-liquid partition 5 
chromatography in which the stationary liquid phase is retained in the apparatus without the use 
of a solid support, was performed with a pH gradient elution to shorten the duration of the 
separation and improve resolution, allowing a very efficient separation of crude alkaloid extract 
(800 mg) from C. fortunei to yield drupacine (16) (9.3 mg), wilsonine (15.9 mg), CET (1) (130.4 
mg), epi-wilsonine (64.8 mg), fortuneine (12.8 mg) and acetylCET (26) (35.6 mg) with 10 
respective purities of 81.2%, 85.7%, 95.3%, 97.5%, 89.1% and 96.2%.65 The recovery of each 
alkaloid was greater than 90%. The extraction step plays an important role in the overall 
purification process of HHT (2). Traditional methods of isolation and purification of the 
chemical constituents of plant tissues have some disadvantages. These approaches require very 
long extraction times and usually a large amount of solvent with sometimes low efficiency. 15 
Furthermore, many natural products are thermally unstable and may degrade during a hot 
extraction. To overcome these drawbacks, a new method of extracting HHT (2) from C. koreana 
assisted by microwave (MWE) was developed by the team of Kim.66 The MWE process of HHT 
(2) recovery (biomass/MeOH 1/6 m/v, 250 rpm) gave a performance of the first biomass 
extraction 25% higher than the conventional solvent extraction (CSE) method for which at least 20 
4 extractions were required. It was possible to recover more than 99% of HHT (2) extracting 
once the biomass by MWE at 40 °C for 15 min or 50 °C for 5 min. Because the content of tars 
and waxy compounds were also increased, an adsorbent was added to the biomass (1/1.5 m/m) 
during the MWE extraction. The use of the microwave extraction process for the extraction of 
HHT (2) when compared to a CSE has many advantages such as shorter extraction time, reduced 25 
amount of solvent, and higher yield resulting in a less costly production system for a superior 
product. A method for ultrasonic-microwave extraction of Cephalotaxus fortunei produced CET 
(1) in a simple, highly efficient and low cost process, suitable for its industrial production in high 
purity after two recrystallizations from anhydrous ethanol.67 
Using a pre-purification method with adsorption prior chromatography, HHT (2) with over 52% 30 
purity can be obtained simply from Cephalotaxus koreana biomass in good yield, minimizing 
the use of solvents, scale and complexity of operations for the final HPLC purification of HHT 
(2) (Table 6).68 This process allows increasing the purity of the raw HHT (2) from 10% to over 
52% with 3 simple steps and inexpensive pretreatment of the MeOH extract. 
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A recent study by Robin related a method for isolation and purification of CET (1) from the 
crude alkaloids extract from 10 kg dry leaves (not from the bark) of C. fortunei var alpina 
(Sichuan, China).69 CET (1) purification was performed for the first time by reverse phase 
HPLC. The crude base (24.5 g) containing 71% of CET (1) was dissolved in a mobile phase 5 
consisting of ortho-phosphoric acid and deionized water containing 1.55% triethylamine (pH 3). 
The acid additive necessitated the alkalization of the obtained aqueous phase and its extraction 
with dichloromethane. Thus, CET (1) (18 g) was fully recovered from the crude alkaloid extract 
as a white solid with an HPLC purity greater than 95%. The limited supply of promising 
secondary metabolites from their natural sources is a major hurdle to their pharmaceutical 10 
development; however, strategies to overcome this problem were developed. For instance, to 
increase the yield of natural anti-cancer drug alkaloids from natural sources, methods of 
extraction are developed. Methods to recover CET (1) from C. harringtonia, var. Fastigiata with 
vegetable oil in the presence of an aqueous carbonate aqueous phase yielded 5% CET (1) with a 
purity of 26%.70 The extraction performed with a mixture of scCO2 (supercritical CO2) with 15 
MeOH-10% Et2NH yielded 0.0029% CET (1) of undescribed purity.
71
 HHT (2) was also 
obtained from C. koreana.72 He et al. have developed a HPLC analysis method for HHT (2) 
determination,73 allowing to reveal three congeners present as impurities in the HHT (2) samples. 
Two impurities are new: α-isoHHT (73) is an isomer of HHT (2) in which the hydroxyl group is 
alpha to the isopropyl group and ethyl-HHT (74), the ethyl ester of HHT (2), is an isolation 20 
artifact of HHT (2) with ethyl acetate, the third being HT (3) (Table 7). α-IsoHHT (73) was 
found concentrated in the crystallization mother liquors of HHT (2) (10.7% against 1–3% in 
crude extracts). The HPLC analysis according to He’s protocol therefore allows the 
determination of HHT (2) in crude samples with a linear response from 4 to 12 µg and a limit of 
quantitation (LOQ) of 27 µg. It was used to assess the purity of several HHT (2) commercial 25 
batches.63 
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A tandem HPLC-electron-spray mass spectrometry (MS-MS) method was developed for the 
analysis of alkaloids contained in the leaves of C. harringtonia. Nine alkaloids bearing an ester 
group were detected with a good sensitivity.74 Content in HT (3) was higher than in HHT (2) in 
the needles of Cephalotaxus griffithii alkaloid fraction (CGAF) (122.14 and 16.79 mg/g of 5 
CGAF, respectively) by HPLC analysis.75 
Another major concern is the enantiomeric purity of cephalotaxine, which could be translated 
into diastereoisomeric purity in its natural ester HHT (2). A process for purification of HHT (2) 
was early developed in view of the clinical studies,63 although recently, a new process for the 
purification of CET (1) allowed the resolution of racemic or partially racemised samples through 10 
formation of various CET salts protonated at N9 with organic anions either chiral such as (2R)- 
and (2S)-malate, (2R,3R)- and (2S,3S)-tartrate, or non chiral such as benzoate, 
hydrogenfumarate, hydrogensuccinate, hydrogenitaconate, hydrogenmaleate, hydrogenmalonate, 
hydrogentartronate, hydrogenmesotartrate, hydrogenglutarate or dihydrogencitrate.69 This study 
also pointed out that the cristalline structure of HHT (2) deposited at the Cambridge 15 
Crystallographic Data Centre (CCDC) exhibits the reverse AC to the commonly accepted one. 
Eventually, selection of a Cephalotaxus cultivar grown in Europe allowed high recovering of 
CET (1) (up to 113–139 g of highly pure cristalline CET (1) from 25 kg of dry leaves).69 
Similarly, ammonium salts of HT (3) and HHT (2) were characterized and, as expected, 
protonation occurred at N9,76 a finding in accordance with biological studies of N-oxides by 20 
Takano61 and mechanistic studies by Seitz (see section 6). 
Apart from the extraction of the natural source, plant cell cultures represent alternative, efficient 
and sustainable chemical factories for the production of biologically important secondary 
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metabolites, especially when the natural source become endangered. The production is limited 
by the low yields associated with harvest and the high costs are associated with complex 
chemical synthesis. Cephalotaxus evergreen trees are somewhat difficult to propagate and they 
are relatively rare. Some of them have been listed in the red list of IUCN (International Union 
for Conservation of Nature) as national plant of second-grade protection in China and are “near 5 
threatened” (C. latifolia), “vulnerable” (C. oliveri, C. mannii) or rare and “endangered” (C. 
lanceolate or C. fortunei Hook. var. lanceolata (K.M.Feng) Silba, C. hainanensis) species.77 A 
variety of strategies are being developed to overcome the limitation of low product yields. In the 
quest of CET raw material, the study of Cephalotaxus crops,78 and development of analysis 
methods of the composition of the different plants were stimulated. A HPLC protocol was used 10 
to determine the content in CET (1), HT (3) and HHT (2) of crop roots and calluses of C. 
harringtonia. As expected, CET (1) is the major alkaloid (10 mg/kg dry matter) while HT (3) 
and HHT (2) are more present in the roots (6.6 and 7.5 mg/kg, respectively).79 
In plant cell and tissue culture, cell growth and product formation are not necessarily correlated, 
tending to give low product yields and slow metabolic rates. Zhang et al. proposed the technique 15 
of periodic oscillation in temperature between 10 and 25 °C every 12 h for 45 days to overcome 
this key problem.80 The total production of HT (3), HHT (2) and isoHT (4) (1.22 mg/L) in solid 
cultures (SoC) of Cephalotaxus fortunei was enhanced by 1.8 and 1.3–fold compared to the 
controls at constant temperatures of 10 or 25 °C. When subjected to such an oscillation every 24 
h for 30 days, suspension cultures (SuC) gave a total alkaloid production of 0.18 mg/L, a 2.0 and 20 
1.05–fold improvement compared to the SuC controls at 10 or 25 °C, respectively. HT (3) 
represents the main alkaloid (72-92% for SoC in 45 days, and 50-67% for SuC for 30 days) 
while HHT (2) is only 4–21% in SoC and 23-40% in SuC, the remaining being isoHT (4).  
In 2014, Li showed that the combination of 10 mg/L sodium fluoride (NaF) as glycometabolic 
regulator and 100 µmol/L methyl jasmonate (MJ) as the elicitor both promoted the biosynthesis 25 
of CET (1) in C. mannii suspension cells.81 NaF was more effective to increase cell membrane 
permeability and product secretion compared to MJ. HT (3) yield in cells was 4.8 greater under 
NaF + MJ conditions than in the control, 1.7–fold greater under NaF and 1.6–fold under MJ 
conditions, respectively (Table 8). No HHT (2) was found in NaF + MJ treated cells. The 
product release rates were 0%, 78%, 24% and 62% in control, NaF, MJ and NaF + MJ treatment, 30 
respectively. The combination of NaF and MJ on cells provided an efficient strategy for 
producing CET (1). 
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Another study of the effects and action mechanisms of NaF on the growth and CET (1) 
production of Cephalotaxus mannii suspension cells indicated that NaF acted as an inhibitor of 
the Embden-Meyerhof pathway (EMP), not as an elicitor to promote CET (1) production.82 
 5 
3. Synthesis of the Alkaloid Core 
The Cephalotaxus alkaloids have drawn the attention of many chemists due to their unique 
structure and potent antileukemic activities of certain ester derivatives they contain. Excellent 
review articles on this subject have been published in this series by Huang and Xue (1984),1 
Miah et al. (1998)2 and more recently, among others, by Nay et al. (2012).6 Since 1997, thirty 10 
nine syntheses of CET (1) have been reported, half of which being asymmetric.  
3.1 Overview 
CET (1) can be described as the superposition of two structural units relevant for synthetic 
strategy choices, namely the pyrrolobenzazepine core ABC 75 and the synthetically challenging 
azaspiro unit CD 76 (Scheme 2). The three stereogenic centers (C3, C4 and C5) are contiguous 15 
on the D ring. Weinreb showed that the stereochemistry of the B/D ring fusion (C4/C5) is 
thermodynamically favoured. In addition, carbonyl reduction of cephalotaxinone (10) delivers 
CET (1) with the natural configuration at C3.83 
 
 20 
Scheme 2 Main strategies to access CET (1) 
 
Thirty-two (twenty-one since 1997 described in this review) syntheses of CET (1) concerned its 
racemic form (Table 9). The number of asymmetric syntheses has grown considerably from only 
three before 1997 to eighteen until 2015, inflecting the development of asymmetric synthesis, 25 
and the efforts to provide a fully synthetic access to the drug (Table 10). The present section 
describes the recent synthetic strategies organized according to the main carbon-carbon bond 
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disconnections of the central azepine ring B (Figure 13). Asymmetric syntheses are also 
classified based on the type of asymmetric center control. The key steps are highlighted for each 
strategy. Most of these syntheses are formal; nevertheless, the overall yield (OY) of each 
synthesis up to CET (1) was evaluated. Eight racemic and five asymmetric syntheses of CET (1) 
are total syntheses, with only one racemic and three asymmetric routes described since mid 5 
1997, with experimental overall yield (OY) and ee. The OY and the number of steps (NS) are 
given from commercially available reagents for comparison purpose. In addition, for convergent 
syntheses, total number of steps (TNS) which represents the total efforts to be accomplished up 
to the target molecule, and the corresponding average yield (AY) are given. Synopses of the 
syntheses of CET (1) reported so far are presented in Table 9 (racemic) and Table 10 10 
(asymmetric). Besides formal syntheses targeting Weinreb’s enamine grouped together in Table 
9, racemic syntheses are classified according to the type of disconnection of ring B (a–e, Figure 
13), then in a chronological order. The asymmetric syntheses are presented in chronological 
order in Table 10. 
 15 
It is apparent from Table 9 that the syntheses of rac-CET (±)-(1) proceed predominantly 
(twenty of thirty-three) by the C4–C13 disconnection a. Most of them are linear, nine only being 
convergent. The most effective total syntheses were described by Kuehne et al.94 in only 11 steps 
and 11.2% OY (average 82% yield per step) or twelve steps and 17.1% OY, by Ishibashi and 
Ikeda et al.138 in 19 steps and 15.6% OY (average > 90% yield per step) and by Chandrasekhar et 20 
al.120 (6.4% OY in 16 steps, 4.7% AY in 18 TNS). The recent formal synthesis by Hong et al. in 
twelve steps and 26.2% OY is the most efficent route.115 The favorite choices as ring A 
precursors are piperonal (82) and homopiperonylic acid (89) with C11 and the methylenedioxy 
group already at the right position.  
 25 
 
Figure 13 Main disconnexions used for the construction of CET ring B 
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Table 10 shows that proline (140) is a widely used chiral source (5 over 21 syntheses), either in 
its natural L form, or in its unnatural D one. Herein, fifteen syntheses are convergent and six are 
linear. The most efficient total syntheses of CET (–)-(1) (OY > 5%) were reported by Weinreb et 5 
al.103 (5.3% OY in 15 steps, 98.5% ee) and by Royer et al.132 (7.5 OY in 16 steps, 98% ee; 5.8% 
AY in 18 TNS). Formal syntheses by Ikeda et al.137 (5.1% OY and AY in 19 steps, 88% ee), by 
Dumas and d’Angelo135 (5.4% OY in 20 steps, >95% ee; 4.1% AY in 22 TNS), by El Bialy et 
al.140 (12.2% OY in 14 steps, 89% ee; 4.3% AY in 20 TNS) and by Trost et al.129 (13.6% OY in 
19 steps, 91% ee; 8.2% AY in 21 TNS) were also efficient. 10 
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3.2 Racemic syntheses 
3.2.1 C4–C13 ring closure a 
The ring closure C4–C13 a (Figure 14) to form the azepine cycle was frequently adopted after 
Semmelhack’s early extensive developments in the second synthesis of rac-CET ()-(1).83 5 
 
 
Figure 14 C4–C13 bond disconnection a for elaboration of CET (1) B ring 
 
3.2.1.1 Tietze’s formal synthesis (1997) 10 
In 1997, Tietze et al.84 reported an efficient synthesis of Mori’s intermediate ()-8885 in which 
rings B and C were constructed by two consecutive intramolecular palladium-catalyzed reactions 
(Scheme 3). The precursor of the D ring and C6–C7–C8 fragment was prepared from 1,3-
cyclopentanedione (77) via its enol ether 78. Addition of the Grignard reagent ()-81 and 
elimination of ethanol followed by tosylation, reduction and acetylation gave the allylic acetate 15 
()-81. Alkylation of the bromoamine 84 prepared in four steps from piperonal 82 with the 
intermediate iodide derivative generated in situ from tosylate ()-81 provided the secondary 
amine ()-85 bearing the AD ring units which contain all carbon atoms and functionalities 
required for synthesis completion. 
 20 
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Scheme 3. Formal synthesis of rac-CET (±)-(1) by Tietze (1997) 
 
A palladium-catalyzed Tsuji–Trost allylation furnished the spiro compound ()-86 containing 
the A and CD ring units. The B ring was formed by a highly stereoselective intramolecular Heck 5 
reaction using Herrmann–Beller catalyst 87. The selective formation of Mori’s tetracyclic 
intermediate ()-88 can be explained by an oxidative addition of the palladium complex to the 
double bond syn to the nitrogen atom followed by a syn elimination of PdH. Mori’s procedure85 
would allow to complete the synthesis of rac-CET ()-(1) in twelve steps (longuest linear 
sequence) and 5.2% OY from 1,3-cyclopentanedione (77) [2.5% AY in fifteen total number of 10 
steps (TNS)]. It should be mentioned that Mori’s protocols differ for the synthesis of racemic or 
optically active CET (1). Indeed, the transformation of desmethylCET (12) into cephalotaxinone 
(10) using 2,2-dimethoxypropane and p-TsOH led to racemization of the product (76% yield). 
On the contrary, when p-TsOH and methyl orthoformiate were used for this transformation at 
room temperature (rt), limited racemization occurred (ee 88%) but the yield went down to 47%. 15 
 
3.2.1.2 Suga and Yoshida’s formal synthesis (2002, 2006) 
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Suga and Yoshida developed an approach to the azaspiro-compound 101 via ring-closing 
metathesis of a functionalized pyrrolidine 100 generated by electrochemical oxidation of α,α-
bis(trimethylsilyl)pyrrolidine 95 (Scheme 4).86,87  
 
5 
Scheme 4. Formal synthesis of rac-CET (±)-(1) by Suga and Yoshida (2002) 
 
First, homopiperonylic acid (89) was used to prepare the A unit 91 bearing a nosylate and an 
aromatic iodide suitable for ring B annulation, relying on Semmelhack’s procedure.83,88 The two 
silyl groups were introduced by Beak’s methodology89 (deprotonation with sec-BuLi and 10 
quenching with TMSCl) furnishing compound 94 which was protected into N-methoxycarbonyl 
compound 95. Its anodic oxidation at low temperature yielded N-acyliminium ion 96, reacting in 
situ with homoallylmagnesium bromide (97) furnishing pyrolidine 98. This latter compound was 
next submitted to a second anodic oxidation followed by direct trapping with the organozinc 
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reagent 99 to provide the diolefin 100. Diene 100 was converted to azaspiro CD unit 101 via ring 
closing metathesis promoted by Grubbs I catalyst. After deprotection using TMSI, the spiranic 
amine intermediate reacted with nosylate 91 obtained from homopiperonylic acid (89) following 
Semmelhack’s procedure.88 
The so-formed aryl iodide ()-102 was submitted to an intramolecular Heck-type ring closing 5 
reaction according to Tietze84 to give Mori’s intermediate ()-88. Applying Mori’s procedure to 
complete the synthesis from intermediate ()-88 would provide an access to rac-CET ()-(1) as a 
linear sequence of 14 steps and 2.2% OY from pyrrolidine 92. 
 
3.2.1.4 Stoltz’s formal synthesis (2007) 10 
Stoltz et al. proposed a concise formal route to rac-CET ()-(1) in which the key spirocyclic 
amine (±)-110 was built through palladium(II)-catalyzed aerobic oxidation (Scheme 5).90 This 
oxidative cyclization and condensation with ring A-containing aldehyde 104 by reductive 
amination were the basis to elaborate both enantiomers of CET (1) and (–)-drupacine (16) (see 
section 3.3.4.3, Scheme 40). 15 
 
Scheme 5. Formal synthesis of rac-CET (±)-(1) by Stoltz (2007) 
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Regioselective bromination of homopiperonylic acid (89) yielded bromocarboxylic acid 103 
converted to Weinreb’s amide,2,83 then reduced by DIBAL to furnish aldehyde 104. Different 
routes were proposed to prepare the ACD ring–containing aryl bromide 86. The best one starts 
from β-ketoester 105 tranformed by reduction to allylic alcohol 10691 which was treated with 
triethyl orthoacetate under Johnson orthoester-Claisen conditions to give ethyl ester 107. 5 
Afterwards, ester 107 was converted in three steps into sulfonamide 108 by successive reduction 
by LiAlH4, tosylation and nucleophilic displacement by tosylamine. The oxidative palladium(II)-
catalyzed heterocyclization of 108 provided efficiently the spirocyclic tosylamide 109 (scale up 
to 1.1 g) whose reductive cleavage of the tosyl group with LiAlH4 furnished the desired 
spirocyclic amine 110. This compound and the aldehyde 104 were coupled by reductive 10 
amination. The resulting tertiary amine ()-86 was converted to the target intermediate ()-88 
using stereoselective Heck conditions described by Tietze.84 Including the four steps of Mori’s 
procedure, this formal synthesis of rac-CET ()-(1) would consist in seventeen steps in 1.6% OY 
from 89. 
 15 
3.2.1.4 Huang’s formal synthesis (2013) 
An efficient synthesis of 1-azaspiro[4.4]nonenes in four steps from γ-butyrolactams (e.g. 113 → 
102, Scheme 6) was developed by Huang et al. in 201392 and applied to the synthesis of rac-CET 
(1), involving Tietze’s Heck ring closure84 of aromatic iodide ()-10286 (Scheme 6). 
 20 
 
Scheme 6. Formal synthesis of rac-CET (±)-(1) by Huang (2013) 
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The γ-butyrolactam 113 was prepared from 2-arylethanol 90 in 65% OY by Mitsunobu’s 
substitution of the primary alcohol, followed by partial reduction of the crude succinimide 112 
with NaBH4 and reductive dehydroxylation of the resulting hemiaminal. Huang’s methodology, 
namely activation of compound 113 by triflic anhydride (2,6-di-tert-butyl-4-methylpyridine 5 
(DTBMP) was the best base for this reaction) followed by successive addition of buten-1-yl 
Grignard (97) and vinyl Grignard reagents provided the desired pyrrolidine 114. The 
hydrochloride salt of the dienyl pyrrolidine 114 was next transformed into the known spiro-
pyrrolidine ()-102 under ring-closing metathesis (RCM) conditions (Grubbs’s generation II 
catalyst). The formal synthesis by Huang et al. was achieved with the synthesis of Mori’s 10 
intermediate ()-88 using the palladium-catalyzed Heck-type cyclization of aryl iodide ()-102 
developed by Tietze84 and employed by Suga and Yoshida.86  Once again, four steps (Mori’s 
protocol)85 have to be performed to obtain rac-CET ()-(1), in order to give a 14 steps pathway 
in 5.4% estimated OY from homopiperonylic acid (89). 
 15 
3.2.1.5 Huang and Wang’s formal synthesis (2015) 
In 2015, Huang and Wang proposed a rapid construction of 1-azaspiro[4.4]nonenone (±)-121 via 
a nitroso-ene cyclization (Scheme 7).93  
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Scheme 7. Formal synthesis of rac-CET (±)-(1) by Huang and Wang (2015) 
 
Reaction of 1,2-epoxycyclopentane 116 with in situ generated dimethylsulfonium methylide 
gave allylic alcohol 106 which was directly used for the subsequent Johnson–Claisen 5 
rearrangement. The resulting ester 107 was subjected to amidation reaction conditions with 
hydroxylamine to afford hydroxamic acid 117. The nitroso-ene cyclization was accomplished 
upon oxidation with tetrapropylammonium periodate via a highly reactive acylnitroso 
intermediate 118 delivering, N-hydroxy-1-azaspiro[4.4]non-2-one 119 which was trapped as an 
acetate 120 yielding in moderate yield spiro-lactam (±)-12190 upon SmI2 reduction. Alkylation of 10 
the sodium salt of (±)-121 with iodoaryl tosylate 115 gave quantitatively (±)-122. The 
subsequent Heck reaction promoted by Herrmann–Beller catalyst 87 proceeded smoothly to 
deliver the ABCD Kuehne’s intermediate94 (±)-123, and the corresponding regioisomeric 
product (±)-124 in 82% combined yield, based on recovered starting material (brsm) as an 
inseparable 54:46 mixture. rac-CET ()-(1) could be obtained in twelve steps from cyclopentene 15 
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oxide (116) and 6.2% OY provided that separation of the regiosiomers is effective and four 
supplementary steps applied to transform the ABCD intermediate (±)-123 (TNS 15 steps, AY 
2.5%, 4.3% brsm). Although Huang and Wang described a rapid access to the CD spirocyclic 
amide (±)-121, Heck ring closure of ring B led to a mixture of two regioisomers and decreasing 
dramatically the yield.  5 
 
3.2.1.6 Nagasaka’s formal synthesis (2002) 
In 2002, Nagasaka et al. reported a formal synthesis of CET (1),95 through a new access to 
Hanaoka’s precursor96 ()-139 (Scheme 8), building successively rings C and B. Ring B was 
installed by ring expansion of pyrroloisoquinoline 132 which resulted from the cyclization of N-10 
acyliminium ion intermediate 131. Alkyne 127 which contains C5, C6, C7 and C8 carbon atoms 
of ring C and C2, C3 and C4 carbon atoms of the CET skeleton was prepared in four steps (63% 
OY) from 4-pentyn-1-ol 125. Coupling of 127 with homopiperonylamine 83 (which could be 
obtained from piperonal 80 in 2 steps and 64% OY), gave amide 128 whose treatment with 
LiHMDS and catalytic amounts of silver triflate gave the AC enamide 129 by intramolecular N-15 
heterocyclization. Oxidation of 129 with dimethyldioxirane delivered the unstable 
methoxylactam 130 immediately treated with BF3OEt2 producing pyrroloisoquinoline 132 via 
the N-acyliminium ion 131. Ring-expansion reaction of the six-membered ring elaborated the 
seven-membered ring B (132  133). Aldehyde 134 was isolated after debenzylation of 133 
followed by Dess–Martin oxidation. The missing C1 carbon atom in aldehyde 134 was 20 
introduced by aldol reaction with the lithium enolate of benzyl acetate. Subsequent oxidation of 
the resulting aldol gave β-keto-ester 135. Formation of ring D was accomplished via Mannich 
cyclisation of N-acyliminium ion 136 and elimination of hydroiodic acid to produce the enone 
138. The final compound of this formal synthesis, spiroketone (±)-139 reported by Hanaoka96 
was isolated after decarbobenzyloxylation followed by catalytic reduction. Application of 25 
Hanaoka’s procedure (3 steps, 34% OY) to complete the synthesis from compound ()-139 
would provide an access to rac-CET ()-(1) in twenty steps and 3.1% OY from 4-pentyn-1-ol 
125. 
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Scheme 8. Formal synthesis of rac-CET (±)-(1) by Nagasaka (2002) 
 
3.2.1.7 Li’s formal synthesis (2007) 
In 2007, Li developed a formal synthesis of rac-CET ()-(1) based on a facile Friedel-Crafts 5 
cyclization of the amido-spiro-cyclopentenone precursor 148 mediated by triflic acid (Scheme 
9).97 
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Scheme 9. Formal synthesis of rac-CET (±)-(1) by Li (2007)  
 
Reaction of acid chlorides 144 and 145 prepared from homopiperonylic acid 86 and 
homoveratric acid 143, with proline-derived spirocyclic amino enone (±)-142 led to the amido 5 
spirocyclopentenones (±)-146 and (±)-148, respectively. Friedel–Craft cyclization of the 
methylenedioxy precursor (±)-146 did not led to compound (±)-147 under various acidic 
conditions due to an electron-deficient aryl system. On the contrary, an efficient Friedel–Craft 
cyclization of the dimethoxy derivative (±)-148 was observed on treatment with triflic acid 
yielding Hanaoka’s intermediate98 (±)-149 isolated in 93% yield. In summary, Li described here 10 
a concise formal synthesis of rac-CET ()-(1) in thirteen steps from L- proline (S)-140 and 4% 
evaluated OY. 
 
3.2.1.8 Yang and Liu’s formal synthesis (2009) 
Yang and Liu reported two strategies to access to intermediate ()-148 involving a [2,3]-Stevens 15 
rearrangement-acid and an acid lactonization sequence as key transformations.99 We describe 
here the best route which led to Li’s intermediate97 ()-148 via the spirolactone 154 (Scheme 
10).  
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Scheme 10. Formal synthesis of rac-CET (±)-(1) by Yang and Liu (2009) 
 
Spirolactone 154 was obtained from methyl prolinate ()-150 by N-allylation with allyl bromide, 
leading to allylamine 151 which underwent a [2,3]-Stevens rearrangement of the resulting 5 
quaternary ammonium salt by reaction with benzyl bromide providing N-benzyl pyrrolidine 152. 
After lactonization of 152 under acidic conditions followed by debenzylation through catalytic 
hydrogenation, spirolactone 154 was acylated with 3,4-dimethoxyphenacetyl chloride (145) to 
produce the amide spirolactone 155 containing the AC ring units, which was selectively reduced 
with LiBH4 to diol 156 in 63.9% OY. Swern oxidation of diol 156 furnished the amido keto-10 
aldehyde 157 which was treated with potassium carbonate to give the amido 
spirocyclopentenone ()-148 with the ACD ring units. This formal synthesis is especially 
suitable for the production of ()-148 at a scale up to 10-50 g. Li97 and Hanaoka’s98procedures (6 
steps, 15% OY) would allow to complete the synthesis of rac-CET ()-(1) in fifteen steps and 
7.1% OY from rac-proline ()-(140). 15 
3.2.1.9 Zhang and Liu’s formal synthesis (2013) 
In 2013, Zhang et al. proposed two pathways for the formal synthesis of rac-CET ()-(1) 
targeting Li’s enone (±)-174100 and Hanaoka’s enone (±)-18096 based on conventional 
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alkylations and aldol condensations from known benzazepines101 165 and 166 obtained in 4 steps 
from aryl amine 83 (bearing a methylenedioxy substituent) or 158 (bearing two methoxy 
substituents), respectively (Scheme 11).102 
 
Scheme 11. Formal synthesis of rac-CET (±)-(1) by Zhang and Liu, the “dimethoxy” route 5 
(2013) 
 
The C ring was elaborated via a N- and C-alkylating annulation by treatment of benzazepine 165 
with 1,3-dibromopropane (167) and Cs2CO3 giving product 168 in one step. ABC dione 172 was 
prepared by alkylation either with allyl bromide followed by Wacker oxidation or more 10 
efficiently with 2-methoxyallyl bromide (170) followed by acidic hydrolysis (Scheme 11). Aldol 
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condensation efficiently constructed the CET (1) core in (±)-173. The dimethoxy groups were 
transformed into the required methylenedioxy group by the usual protocol85 to afford ABCD 
enone (±)-174 reported by Li in 2003.100 Application of Li and Weinreb’s103 procedures would 
end up a synthesis of rac-CET ()-(1) in seventeen steps from homoveratryl amine (158) and 
2.2% calculated OY.  5 
These authors also studied the use of methylenedioxybenzazepine 166 as starting material 
(Scheme 12). 
 
 
Scheme 12. Formal synthesis of rac-CET (±)-(1) by Zhang and Liu, the “methylenedioxy” route 10 
(2013) 
 
Ring C was elaborated by acylation/alkylation of benzazepine 166 with 3-chloropropanoyl 
chloride (175) to furnish the ABC ketone 176. Treatment with sodium hydride and 2-
methoxyallyl bromide (170) produced the enol ether 177 (74%) as a major O-alkylated product 15 
along with the desired C-alkylation derivative 178 (22%). Claisen rearrangement allowed 
conversion of 177 to 178, which was exposed to acid hydrolysis to give dione 179. 
Intramolecular aldol condensation provided the known amido enone ()-18096 in 95% yield. 
Formally, rac-CET ()-(1) could be obtained following Hanaoka’ synthesis96 in a total of sixteen 
steps from homopiperonylic acid (89) and 2.5% estimated OY. 20 
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3.2.1.10 Bubnov’s formal synthesis (2008) 
Bubnov et al. developed a convenient and practical methodology for the preparation of various 
spiro-β-amino alcohols. This procedure was applied to a formal synthesis of rac-CET ()-(1) 
involving allylboration and RCM to prepare the CD ring containing azaspirobicyclic compound 
183 (Scheme 13).104 5 
 
 
Scheme 13. Formal synthesis of rac-CET (±)-(1) by Bubnov (2008) 
 
2-Pyrrolidone (181) was converted to 2,2-diallylated pyrrolidine 182 by addition of 10 
triallylborane. After amine protection, RCM was accomplished with Grubbs I catalyst providing 
azaspirocyclic carbamate 183 in high yield (three steps, 87% OY). Treatment of 183 with NBS 
produced tricyclic bromoamide 184. After t-butoxide mediated dehydrobromination affording 
the spiro olefin 185, an allylic isomerization in the presence of MgBr2 gave 186 as the sole 
isomer. Hydrolysis of 186 and acylation with acid chloride 145 were performed in a one-pot 15 
procedure leading to 187. Mori’s ACD intermediate, generated by reduction of amide 187 with 
LiAlH4, was allowed to cyclise into ABCD compound (±)-188 by treatment with PPA. Then, the 
synthesis of rac-CET ()-(1) in sixteen steps from 2-pyrrolidone (181) and 3.8% estimated OY 
could be completed using Mori’s sequence85 as the final steps. 
 20 
3.2.2 N9–C5 ring closure c 
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Figure 15. C5-N9 bond disconnection c for construction of ring B of CET (1) 
3.2.2.1 Li’s formal syntheses (2003-2005) 
From 2003 to 2005, Li et al. reported three formal syntheses, two of them via the same 
intermediate 192 (Scheme 14).100,105 Formation of ring B and D was achieved by transannular 5 
reductive skeletal rearrangements.  
 
 
Scheme 14. Formal synthesis of rac-CET (±)-(1) by Li (2003) 
 10 
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Starting from piperonyl amine 83, diester 189 was obtained in four steps via a Bishler–
Napieralski cyclisation followed by hydrogenation and N-alkylation with ethyl 4-bromobutyrate. 
A second N-alkylation with allyl bromide led to the ammonium salt intermediate 190 which was 
transformed via a 2,3-sigmatropic Stevens rearrangement into diester 191. Eventually, compound 
193 was obtained by a Dieckmann cyclization with subsequent decarboxylation followed by 5 
Wacker oxidation. Aldol condensation of the dione 193 provided the spirocyclic AD enone 194 
(Scheme 14). CET (1) B and C rings were formed by reductive rearrangement in acetic acid via 
the aziridinium ion 195. The obtained ABCD ketone (±)-197 (revised stereochemistry at C4 as 
drawn) was oxidized with phenyliodonium diacetate (PIDA) to give acetal (±)-198 which, after 
hydrolysis, was submitted to autoxidative dehydrogenation with potassium t-butoxide and 10 
oxygen to provide the desmethylcephalotaxinone (±)-12. Formally synthesis of rac-CET ()-(1) 
could be achieved according to Weinreb103 using two additional steps, leading to a formal total 
synthesis in 1.6% calculated OY over eighteen steps from piperonal (82). 
An alternative approach to ketone (±)-197 was described from allyl ketone 192. Clemmensen 
reductive rearrangement of this ketone first led to benzazepine derivative 199 (Scheme 15).100  15 
 
 
Scheme 15. Formal synthesis of rac-CET (±)-(1) by Li (2003): alternative synthesis of ketone 
(±)-197 
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After Wacker oxidation of compound 199, application of Polonovski–Potier reaction conditions 
to 200 gave the enamine 201. It was previously reported that cyclization of this intermediate to 
(±)-174 (formally an endocyclic enamine annulation) could only be realized in low yield. Li 
found that an aerobic treatment of 201 with Fe2+ salt in acetic acid promoted the cyclization into 
ABCD enone (±)-174 in good yield. This cyclization can be seen as an unusual azo-Nazarov-25 
type cyclization. A catalytic hydrogenation eventually gave ketone (±)-197. This synthesis in six 
steps and 14.5-17% OY from 192 is not advantageous when compared to the three steps and 
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40.5% OY version presented in Scheme 14. Thus, formal synthesis of rac-CET ()-(1) following 
this procedure could be theoretically achieved in twenty-one steps and 0.6–0.7% OY from 
piperonal (82).  
In 2005, Li et al. described a formal synthesis of the Dolby-Weinreb enamine103,106 203 from 
dione 193, with a mild Clemmensen–Clemo–Prelog–Léonard reductive rearrangement of 193 as 5 
the key step (Scheme 16).105 
 
 
Scheme 16. Formal synthesis of rac-CET (±)-(1) via Dolby-Weinreb enamine 203 by Li (2005) 
 10 
Dehydrogenation of the benzazepine 202 by Hg(OAc)2 gave enamine 203 which could be likely 
transformed in rac-CET ()-(1) by Weinreb’s strategy103 in expected 0.4% OY for seventeen 
steps from piperonal (82). Reductive rearrangement of amino dione 193 also produced amino 
ketone 200 in 15% yield, which could be processed into demethylcephalotaxinone (12) then into 
CET (1) through a nine-stage sequence. This constitutes another formal synthesis of CET (1) 15 
with an expected OY of 0.15% in twenty three steps from piperonal (82).  
In 2005, Li reported a novel synthesis of the amino enone 194 involving annulation of the readily 
available aminodione 193 (Scheme 17).107  
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Scheme 17. Formal synthesis of rac-CET (±)-(1) via amino enone 194 by Li (2005) 
 
Bischler–Napierralski condensation of amine 83 with δ-valerolactone (204) mediated by POCl3 
gave the iminium ion 205 in 74% yield. Treatment of 205 with aqueous NaOH generated a labile 5 
enamine 206 which was alkylated with bromoacetone to give the keto enamine 207 (20%) and 
the iminium bromide 208 (50%). Both were transformed by treatment with 70% perchloric acid 
into iminium perchlorate 209 which upon exposure to NaOH furnished the unexpected dione 193 
(25%) and annulated cis-cyclopentanone 210. Both compounds can be transformed to 194 by 
standard procedures (aldol condensation from 193, selenoxide elimination from 210 (15%). 10 
Formally, rac-CET ()-(1) could be obtained according to Li’s and Weinreb‘s protocols100,103 
with a calculated 0.7% OY for sixteen steps from piperonal (82). The ABCD ring construction 
by rearrangement can be regarded as a biomimetic synthesis. 
 
3.2.2.2 Tu and Zhang’s formal synthesis (2009) 15 
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In 2009, Tu and Zhang developed a synthesis of Li’s intermediate dione100 193 based on an 
intramolecular Schmidt reaction of symmetric azido dione 221 (Scheme 18).108  
The synthesis started with compound 213 (ring A precursor) obtained from homopiperonylic 
acid (89) by reduction, bromation and chlorination,109 and iodo cyclopentenone 215 (ring D 
precursor) prepared by iodination of cyclopentenone (214) (Scheme 18).110 Suzuki–Kumada 5 
coupling of an aryl boronic acid prepared from 213 with 2-iodocyclopentenone (215) afforded 
enone 216 in 81% yield. Alcohol 217 obtained by Grignard addition on enone 216, was 
transformed to the azide 220 on treatment with sodium azide in the presence of sodium iodide. 
Epoxidation and protection with TMSCl led to siloxy epoxy azide 219 in 63% OY from 216. 
Treatment of epoxide 219 with TiCl4 afforded β-hydroxy ketone 220 which was oxidized with 10 
Dess Martin’s reagent (70% yield, 2 steps). The key intramolecular Schmidt reaction was applied 
to dione 221 giving the amide 222. The terminal double bond in 222 was converted into a methyl 
ketone by Wacker oxidation. Selective reduction of an intermediate thiolactam, prepared from 
amide 223 with Lawesson’s reagent, using Raney Ni afforded the expected tertiary amine 193 
described by Li.100,107 An aldol cyclisation gave the key enone 194 in 80% yield. rac-CET ()-15 
(1) could be obtained by Li’s and Weinreb’s procedures in twenty three steps from 
homopiperonylic acid (89) and 1.9% evaluated OY. 
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Scheme 18. Formal synthesis of rac-CET (±)-(1) by Tu and Zhang (2009) 
 
3.2.2.3 Li’s formal synthesis (2011) 
The new synthetic strategy described by Li et al. in 2011 was based on a facile reductive oxy-5 
Nazarov (RON) cyclization as a key step (Scheme 19).111 Condensation of norhydrastinine 
(224), prepared in four steps from piperonal (22.8% OY), with iodo enolsilane 225 afforded the 
aldehyde 226 which was exposed to 2,2,2-trichloroethyl chloroformate (227) to give the 
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macrocyclic enal 228. Wittig olefination with triphenylphosphoranylidene dioxolanone 229 
furnished the ten-membered amide 230 with the exocyclic (E)-olefin in 68% isolated yield, along 
with the separable (Z)-isomer (14%). Mild hydride reduction led to hydroxy enone 232 
presumably via the oxonium ion 231 which could underwent rapid and effective 4π 
electrocyclization. Acetylation of the hydroxyl function of the resulting compound 232 followed 5 
by selective cleavage of the N-Troc group by zinc reduction led to the spontaneous formation of 
ABCD unit 233 as a single diastereomer by an intramolecular aza-Michael addition. Air-
oxidation in the presence of potassium t-butoxide gave rac-demethylcephalotaxinone (±)-(12). 
Application of Weinreb’s method103 would allow to synthesise rac-CET ()-(1) in thirteen steps 
from piperonal (82) and 0.4 OY. 10 
 
 
Scheme 19. Formal synthesis of rac-CET (±)-(1) by Li (2011) 
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3.2.2.4 Jiang’s formal synthesis (2013) 
In 2013, Jiang et al. described the construction of the cyclopentenone D ring of rac-CET ()-(1) 
by an intermolecular Pauson–Khand reaction (Scheme 20).112 Iodo alcohol 90 was first protected 
as a mesylate and submitted to mild Sonogashira conditions to afford the alkyne 235. The 5 
intermolecular Pauson–Khand reaction of alkyne 235 with ethylene could generate two 
regioisomeric products. Only the desired isomer 236 (58% yield) was obtained under optimized 
conditions using n-butyl methyl sulfide as a promoter with dimethyl sulfoxide as the oxidant. 
Oxidation of alcohol 236 followed by reductive amination produced the amine 238 which was 
advanced to the ten-membered ring compound 239 by intramolecular N-alkylation. Mariano’s 10 
intermediate113,114 240 was prepared successively by deprotection and re-protection with a t-
butoxycarbonyl group. 
 
 
Scheme 20. Formal synthesis of rac-CET (±)-(1) by Jiang (2013) 15 
 
This strategy led quickly and efficiently to macrocyclic precursor 240 in eight steps and 20% 
OY. With this compound 240 in hand, a formal synthesis of rac-CET ()-(1) was thus attained, 
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and additional five-step sequence113,114 would give rac-CET ()-(1) over fifteen steps from 
homopiperonylic acid (89) and 4.3% estimated OY.  
3.2.3 Other strategies for ring B formation 
3.2.3.1 C4-C5 ring closure b: Hong’s formal synthesis (2015) 
 5 
Figure 16. C4–C5 bond disconnection b for elaboration of ring B of rac-CET (±)-(1) 
 
Recently, Hong et al. reported two formal syntheses115 involving an unusual C4–C5 
disconnection116,117,118 for ring B formation. The key steps were first an N-acyliminium ion 
cyclization which established stereogenic centers C5 and C4 and the formation of B ring. Then a 10 
RCM furnished the spiro-ring D (Scheme 21). The two syntheses started from iodo alcohol 90 
prepared from homopiperonylic acid (89) in two steps. 
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Scheme 21. Formal synthesis of rac-CET (±)-(1) by Hong via Kuehne’s intermediate (±)-123 
(2015) 
 
Sonogashira coupling of aryl iodide 90 with propargyl trimethylsilane catalyzed by palladium(II) 
and copper(I) iodide delivered alkyne 242 in excellent yield (97%). After a catalyst screening, 5 
partial hydrogenation was carried out with “P-2 Nickel” and ethylenediamine (Brown catalyst) 
leading to (Z)-243 in quantitative yield (dr > 15/1). Mitsunobu reaction with succinimide, 
followed by allylation next gave the hemiaminal 246 which, treated with TiCl4 at low 
temperature in mesitylene, allowed for the generation of an N-acyliminium ion which cyclized to 
furnish the ABC unit 247 (cis/trans 2.5/1). Zhan’s catalyst-1B119 was the most effective for the 10 
RCM reaction to deliver Kuehne intermediate94 (±)-123. Formally, synthesis of rac-CET ()-(1) 
could be achieved by Kuehne’s protocol94 in twelve steps from homopiperonylic acid (89) and 
23.5% calculated OY.  
Since iminium ion cyclisation showed a moderate diastereoselectivity and the separation of the 
two diastereomers by silica gel chromatography failed, this route was less attractive. To improve 15 
it, authors investigated cyclization from the E-allylsilane 249 obtained by Suzuki coupling 
between compound 248 and aryl iodide 90 catalyzed by palladium (Scheme 22). As previously 
seen, a Mitsunobu reaction gave 250. Subsequently, 250 was treated with a Grignard reagent and 
cyclized by a Hosomi–Sakurai reaction to 251. 
Through a TiCl4 promoted iminium ion cyclization, the ABC pyrrolobenzazepine 251 was 20 
obtained with a ratio of 20/1 in favor of the trans-isomer. The RCM reaction of the trans-isomer 
of amide 251 did not happen whatever the catalysts used. Reduction of the amide led to a less 
rigid tertiary amine 252, suitable for the desired cyclization. Metathesis proceeded smoothly in 
the presence of camphor sulfonic acid (1 equiv.) to protonate the amine and Zhan-1B’s catalyst 
(1 mol %). The ABCD ring system 253 was obtained with inverted relative stereochemistry at 25 
C4. Dihydroxylation and Swern oxidation afforded the known demethylcephalotaxinone ()-
(12). Application of an improved Weinreb’s procedure103 would generate rac-CET ()-(1) in 12 
steps and 26.2% expected OY from homopiperonylic acid (89). 
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Scheme 22. Formal synthesis of rac-CET (±)-(1) by Hong via Weinreb’s intermediate ()-12 
(2015) 
 
3.2.3.2 N9-C10 ring closure e: Chandrasekhar’s total synthesis (2016) 5 
 
Figure 17. N9–C10 bond disconnection e for construction of CET (1) B ring 
 
In 2016, Chandrasekhar et al. developed a total synthesis of rac-CET ()-(1) via an aryne 
insertion from the benzyne precursor 255 into β-ketoester 257 as a key step to build the complete 10 
set of carbon atoms and functionalities to end up the synthesis of rac-CET ()-(1) (Scheme 
23).120  
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Scheme 23. Total synthesis of rac-CET (±)-(1) by Chandrasekhar (2016) 
 
Aldehyde 256 derived in five steps from L-proline (140) was transformed into β-ketoester 257 
by Roskamp conversion. Then, β-ketoester 257 was submitted to [2+2] cycloadditon with 5 
benzyne generated from aryne precursor 255. The unstable benzocyclobutane 258 underwent C–
C bond cleavage leading to compound 259. At this point, all carbons atoms of the CET (1) 
skeleton were introduced. The synthesis of ABCD enone 262 was accomplished by Wacker 
oxidation, aldol condensation, ester hydrolysis, Boc deprotection and amidation. Reduction, 
followed by oxidation gave Hanaoka’s intermediate98 (±)-147. From proline (140), rac-CET ()-10 
(1) was obtained through intermediate 147 applying litterature conditions98 in a total of sixteen 
steps and 6.4% OY. Including the preparation of aromatic unit 255 from 5-benzodioxolol (254), 
rac-CET ()-(1) was obtained in eighteen total number of steps and 4.7% AY. 
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3.3 Syntheses of enantioenriched CET 
Synthesis of optically pure CET (1) remains a challenge for organic chemists. Three contiguous 
asymmetric centers including a tetrasubstituted one on D ring have to be controlled. It was early 
noticed by Weinreb103 that racemic syntheses led to only one diastereoisomer without any 5 
required separation. This means that the configurations of the three asymmetric centers are 
mutually controlled. Strategies using disconnection C4–C5 for B ring formation exemplify this 
phenomenon. During the cyclisation step, the thermodynamically more stable BD ring junction 
is cis, which is the relative C4–C5 configuration found in natural cephalotaxine. Moreover, 
Weinreb also showed that NaBH4 reduction of cephalotaxinone (10) is stereoselective (Scheme 10 
24), delivering the required relative stereochemistry of the hydroxyl function at C3 of CET (1) 
which is assumed to be formed as a result of hydride attack from the convex face of 10. 
 
 
Scheme 24. Stereoselective reduction of cephalotaxinone (10) 15 
 
It is thus possible to control successively the C4 center via the C5 tetrasubstituted center then the 
C3 center via the C4 stereocenter, and consequently, control of the tetrasubstituted C5 
stereocenter is the only necessary one to synthetize enantiomerically pure CET (1). Most of 
asymmetric syntheses are based on the control of this spiro center followed by a stereoselective 20 
cyclisation affording the B ring and C4 control, a final reduction establishing the desired 
configuration at C3. The asymmetric syntheses of CET (1) described below are classified 
according to the type of stereochemical control (asymmetric catalysis, use of chiral auxiliaries, 
incorporation of chiral building blocks and resolution strategies) and in chronological order in 
each section. 25 
 
3.3.1 Asymmetric catalysis 
3.3.1.1 Tietze’s formal synthesis (1999) 
In 1999, Tietze et al. reported an asymmetric version of their previous synthesis84 using Corey’s 
oxazaborolidine 267 to reduce enantioselectively ketone 266 (Scheme 25).121 Ketone 266 was 30 
prepared by bromination of cyclopentane-1,3-dione (77) with potassium bromate followed by 
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treatment with a large excess of Grignard reagent prepared from chloroalcohol 265 and 
tosylation (three steps, 40% OY). Chiral bromo-acetate 268 corresponding to the future D ring 
was obtained by reduction with diborane in the presence of catalytic amounts of the chiral 
oxazaborolidine 267, followed by acetylation of the allylic alcohol. A 87% enantiomeric excess 
(ee) was measured by NMR using Eu(hfc)3. Formation of the B and C rings was achieved by the 5 
strategy described for rac-CET ()-(1), employing two successive Pd-catalyzed transformations. 
The optically active form of Mori’s intermediate85 (–)-88 was isolated. The synthesis of CET (–)-
(1) could be likely achieved in thirteen steps linear sequence, 3.1% calculated OY and 87% 
expected ee from cyclopentane-1,3-dione (77). 
 10 
 
Scheme 25. Formal asymmetric synthesis of CET (–)-(1) by Tietze (1999) 
 
3.3.1.2 Tu’s formal synthesis (2012) 
In 2012, Tu et al. developed a formal synthesis of CET (–)-(1) targeting Mori’s intermediate85 (–15 
)-88 which was built from 1-azaspirocycle (–)-109 by a tandem hydroamination/semipinacol 
rearrangement reaction. At the same time, chirality was introduced using a chiral silver 
phosphate (R)-273 as catalyst (Scheme 26).122 
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Scheme 26. Formal asymmetric synthesis of CET (–)-(1) by Tu (2012) 
 
The anion of butyne 270 prepared from trimethylsilylacetylene (269) reacted with cyclobutanone 5 
to give 272 which was submitted to a cyclisation-rearrangement. The key reaction was readily 
performed using chiral silver phosphate 273 to give azaspirocycle 275 in very good yield and 
80% ee. The ketone 275 was transformed into vinyl triflate 276, followed by reduction to lead to 
the key intermediate (R)-109 reported by Stoltz et al. (see 3.2.1.3).90 Elimination of the tosyl 
group generated the amine (R)-110 which reacted with bromo aldehyde90 104 (see Scheme 5) 10 
under reductive amination conditions to give Tietze’s intermediate121 (R)-86. Application of the 
Tietze’s procedure led to Mori’s alkene (–)-88 in 80% ee determined by chiral HPLC. 
Surprisingly, during its purification by column chromatography on silica gel, authors found that 
enantiomers could be separated leading to (–)-88 in 35.5% yield with >99% ee. This 
phenomenon called “self-dispropornation of enantiomers” results from different affinities of 15 
aggregates of compound 88 on silica gel.123 Tu thus accomplished a formal synthesis of CET (–)-
(1) in thirteen steps, 3.3% calculated OY and 80% ee. The high purity material (estimated 99% 
ee) could be obtained in 1.7% calculated OY from trimethylsilylacetylene (269). 
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3.3.1.3 Renaud’s formal synthesis (2012) 
In 2012, Renaud et al. reported two variants for the formal synthesis of CET (–)-(1).124 Both 
syntheses were based on a stereoselective carboazidation of methylene cyclopentanol 
derivatives. In the first approach, which will be described later (see section 3.3.5.2, Scheme 43), 5 
the starting material was obtained from the racemate by resolution. The second approach was 
more efficient and started with (S)-cyclopentenol (284) obtained in 96% ee set up via 
enantioselective Noyori’s hydrogenation of propargylic ketone 280 using (S,S)-1,1'-bi-2-
naphthol 281 to give 282. Compound 282 was obtained in 64.5% yield from 4-pentenoic acid 
(277) (Scheme 27).125 10 
Dihydroxylation of silyl enolate (S)-285 afforded the diol 286 as a single diastereoisomer which 
was protected as an acetonide. Desilylation, oxidation and Wittig methylenation afforded the 
bicyclic alkene 287 which was submitted to radical carboazidation.The azido ester 289 was 
obtained in high diastereoselectivity (dr > 97:3) resulting from exo-selective azidation of the 
bicyclic intermediate radical 288. The spirolactam 290 was obtained by reduction of the azide. 15 
First, the stereogenic center at C5 (cephalotaxine numbering) of (S)-cyclopentenol 284 was used 
to control the configuration of the newly formed diol at C1–C2, and then it was destroyed upon 
double bond formation in 287. This chiral center was eventually controled during the 
carboazidation step leading to 289. This sequence corresponds to the concept of self-regeneration 
of stereogenic centers.126 Reduction of the lactam 290 gave an amine which was N-alkylated 20 
with nosylate 91 (see Scheme 4) to afford the ACD aryl iodide 291. After hydrolysis of the 
acetonide, the diol was converted to thionocarbonate 292 which on treatment with Corey–
Hopkins’ reagent afforded the desired alkene (R)-102. It was noteworthy that no racemization 
took place during the synthesis of alkene (R)-102. Optically active alkene (R)-102 was already 
prepared by Mariano127,128 (Scheme 42) and, in its racemic form, by Suga and Yoshida86 25 
(Scheme 4).  
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Scheme 27. Alternative formal asymmetric synthesis of CET (–)-(1) by Renaud (2012) 
 
Formation of ring B via Heck intramolecular reaction according to Tietze’s procedure afforded 
Mori’s intermediate85 (–)-88. Synthesis of CET (–)-(1) could be likely achieved in 97% ee within 5 
twenty-six steps from 4-pentenoic acid (277) and 0.85% expected OY. 
 
3.3.1.4 Trost s formal synthesis (2012) 
In 2012, Trost et al. developed an enantioselective palladium-catalyzed [3+2] cycloaddition of 
trimethylenemethane (TMM) with a nitroalkene and described an application to the synthesis of 10 
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the enantiopure AD unit (+)-297 (Scheme 28),129 which racemic form is an intermediate in 
Ikeda’s synthesis.130  
 
Scheme 28. Formal asymmetric synthesis of ent-CET (+)-(1) by Trost (2012) 
 5 
The phosphoramidite ligand 296 provided the chirality during the [3+2] cycloaddition, delivering 
compound (+)-297 in 91% ee (chiral HPLC). Transformation of compound ()-297 into rac-CET 
(1) had been previously reported by Ikeda, and formally, ent-CET (+)-(1) (enantiomer of the 
natural product) could be obtained in 91% expected ee and 13.6% calculated OY over a nineteen 
steps in the longest linear sequence from piperonal (82).  10 
 
3.3.2 Use of chiral auxiliary 
3.3.2.1 Royer’s total synthesis (2004) 
In 2002, Royer et al. described an asymmetric synthesis of azaspiro compound (–)-303, 
containing the CD ring fragment exploiting a stereoselective semi-pinacolic reaction as the key 15 
step.131 In 2004, these authors developed an enantioselective synthesis of (–)-CET (–)-(1) from 
spirolactam ketal (–)-306,132 relying on Kuehne94 and Nagasaka’s133 procedures (Scheme 29). 
The immolative removal of the chosen chiral inducer, (S)-1-(1-naphthyl)ethylamine (298), did 
not allow the recovery of this chiral material. 
 20 
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Scheme 29. Asymmetric synthesis of CET (–)-(1) by Royer (2004) 
 
The silyloxypyrrole 300 prepared from 2,5-dimethoxy-2,5-dihydrofuran (299) over two steps 
using (S)-1-(1-naphthyl)ethylamine (299) as the chiral source, was subjected to a vinylogous 5 
Mukaiyama aldol reaction with cyclobutanone (271) affording the α,β-unsaturated γ-lactam 301. 
On treatment with concentrated HCl, a semipinacolic rearrangement of 301 furnished the desired 
spiro compound (–)-303. The N-acyliminium ion 302 was attacked preferably anti to the naphtyl 
group, delivering compound (–)-303 with a good diastereoisomeric excess (de 80%). The major 
diastereoisomer was recrystallized and also easily recovered by chromatography, thus 10 
azaspirononanedione (–)-303 was obtained in 70% yield and de surpassing 99%. The ketone 
function of (–)-303 was protected as a cyclic ketal, then reductive cleavage of the N-benzylic 
bond provided spirolactam ketal (–)-304. N-alkylation of its sodium salt with the tosylate 305 of 
3,4-methylenedioxypheny-2-ethanol116,117,118,134 followed by ketal hydrolysis afforded the 
enantiopure ACD intermediate (–)-306 described by Kuehne in its racemic form.94 Following 15 
Kuehne’s procedure, compound (–)-306 was transformed into (–)-CET (1) with improved 
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formation of enone (–)-307 using a stoichiometric amount of Pd(OAc)2 without benzoquinone 
(83% yield). A further modification consisted in the use of AlH3
96 at 0 °C instead of LiAlH4 in 
refluxing THF for the reduction of (–)-308 in order to avoid any racemization of sensitive CET 
(1). CET (–)-(1) was thus obtained in 98.7% ee and 7.5% OY over a sixteen steps linear 
sequence from 2,5-dimethoxy-2,5-dihydrofuran (299) using (S)-1-(1-naphthyl)ethylamine (298) 5 
as a chiral source. 
 
3.3.2.2 Dumas and d’Angelo’s formal synthesis (2005) 
After having explored ABC → ABCD synthetic strategies,116,117 in 2005, Dumas and d’Angelo 
et al. reported a novel enantioselective synthesis of the azaspiro ring unit CD (–)-304 described 10 
by Royer132 based on an asymmetric Michael reaction involving a chiral enamine prepared from 
recyclable enantiopure (R)-1-phenylethylamine 309 (Scheme 30).135 As a consequence of 
stereogenic control of the quaternary carbon center in the resulting (R)-keto diester 311, the two 
asymmetric centers C3 and C4 of CET (–)-(1) were formed with their natural ACs. Similarly, use 
of the antipodal (S)-1-phenylethylamine (309) could afford ent-CET (+)-(1), although it would 15 
lead to biogolically inactive esters.136 The key step was a Curtius rearrangement of acyl azide 
314 which allowed installation with perfect stereochemical fidelity and high efficiency of an α-
nitrogen substituent at the tetrasubstituted center in ketodiester 311 to set the terasubstituted 
spirocyclic center. 
 20 
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Scheme 30. Formal asymmetric synthesis of CET (–)-(1) by Dumas and d’Angelo (2005) 
 
The keto diester (R)-311 was elaborated in 85% yield and an ee ≥ 95% through Michael addition 
of enamino ester (R)-310 to methyl acrylate. Sequential stereoselective Luche reduction of the 5 
ketone at low temperature followed by saponification, and acidicification provided an 
intermediary hydroxy diacid which upon spontaneous lactonization generated the 
diastereomerically pure lactone acid 313 obtained in 75% yield. The two ester functions of 311 
were differentiated at this stage. The acid 313 was first converted into acyl azide 314 which was 
directly rearranged into the benzyl carbamate 315 by treatment with benzyl alcohol at 110 °C. 10 
Saponification followed by oxidation with in situ generated ruthenium tetroxide then 
esterification of the intermediate acid by diazomethane afforded the keto ester (R)-316. This 
compound was converted into ketal then submitted to hydrogenolysis to deliver the target 
spiroketal amide (–)-304. By relying on Royer132 and Kuehne’s procedures,94 using tosylate 305 
obtained in 2 steps and 76.5% OY from safrole (317)117,118 via 2-arylethanol 211, the synthesis of 15 
CET (–)-(1) could be achieved in expected ee ≥ 95%, twenty steps from β-ketoester 105 and 
calculated 5.1% OY (Scheme 30). 
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3.3.3 Incorporation of chiral sources 
3.3.3.1 Ikeda’s formal synthesis (1999) 
In 1999, Ikeda et al. developed an asymmetric version137 of their racemic synthesis.130,138 The 
intermediate ABCD ketone (+)-149 was prepared from unnatural D-proline (R)-140 used to 
furnish the C ring with C4 atom and to control the C5 tetrasubstituted stereogenic center set in 5 
319 (Scheme 31). 
 
 
Scheme 31. Formal asymmetric synthesis of CET (–)-(1) by Ikeda (1999) 
 10 
Compound 318 obtained from D-proline (R)-140 according to Seebach139 was stereoselectively 
allylated to give oxalolidinone 319 which reacted with 5-lithiobenzodioxole (320), generated 
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from 4-bromobenzodioxole (itself prepared from benzodioxole 330) and n-BuLi at –78 °C. 
Then the intermediate aminoketone was protected to give the AC ring unit found in 321. Wacker 
oxidation, followed by aldol condensation of dione 322 generated the D ring of CET (1) 
characteristic of the α,β-unsaturated ketone 323. Catalytic diastereoselective hydrogenation 
provided the cyclopentanone 324 with the desired absolute configuration at C4 and C5. 5 
Eventually, Ikeda applied his racemic strategy130,137 to build the B ring in six steps using a 
Pummerer reaction for closure of B ring (327 → 328). Hanaoka’s intermediate (+)-147 was 
obtained in two steps by treatment with K2CO3 and Swern oxidation. Ikeda proposed a formal 
synthesis of CET (–)-(1) in 88% estimated ee (HPLC), nineteen steps from D-proline (R)-140 
and 5.1% expected OY. 10 
 
3.3.3.2 El Bialy’s formal synthesis (2002) 
In 2002, El Bialy described a formal synthesis of CET (–)-(1), where formation of the B ring 
involved a palladium catalyzed cyclization leading to Hanaoka’s98 ketolactam intermediate (+)-
147 (Scheme 32).140 The optically active ACD iodoaryl enone 329 was prepared from D-proline 15 
(R)-140 by Seebach’s method139 relying on Ikeda’s procedure. Using 20 mole % Pd(OAc)2, 
PPh3, Et3N and formic acid in THF allowed the intramolecular reductive Heck reaction to furnish 
the ketolactam (+)-147 in 76% yield, a noticeable improvement compared to Ikeda’s 
method130,137 whose catalysis implying Pd(OAc)2 in the presence of PBu3, dppp, Ag2CO3 in 
DMF led to (+)-147 in a modest 7% yield.  20 
 
 
Scheme 32. Asymmetric formal synthesis of CET (–)-(1) by El Bialy (2002) 
 
This formal synthesis would deliver CET (–)-(1) in expected 89.3% ee over a fourteen steps 25 
linear sequence from D-proline (R)-140 and an evaluated 12.2% OY. 
 
3.3.3.3 Hayes’s formal syntheses (2008) 
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In 2008, Hayes et al. developed a formal synthesis of CET (–)-(1) based on an alkylidene 
carbene 1,5-CH insertion reaction as a key step to construct the 1-azaspiro[4.4]nonane CD ring 
system (338 → 339).141 In a first approach, vinyl chloride 338 was chosen as a carbene precursor 
prepared in seven steps and 50% OY from L-proline (S)-(140) via N-Boc-proline methyl ester 
331 (Scheme 33).  5 
DIBAL-H reduction of 331 followed by Wittig reaction with 1-triphenylphosphoranylidene-2-
propanone (332) gave an intermadiate E-enone. Catalytic hydrogenation and a second Wittig 
reaction with chloromethylenephosphorane (334) afforded the vinyl chloride 335. After 
deprotection of the amine, amide formation with the carboxylic acid 89 and reduction of the 
resulting amide 337 led to the pivotal alkylidene carbene precursor 338. Its treatment with 10 
KHMDS caused the key alkylidene carbene 1,5-CH insertion reaction leading to the desired 
azaspiro[4.4]nonane derivative 339 in good yield (65-79%). Regioselective iodination of the 
aromatic ring system gave the Heck-cyclization precursor 340. Its X-ray crystal structure 
allowed the confirmation of its absolute stereochemistry, thus demonstrating that as expected the 
1,5-CH insertion reaction had proceeded with retention of configuration. The Heck cyclization 15 
under modified Fu’s conditions (Pd(OAc)2, HBF4•PtBu3, Cs2CO3) delivered the ABCD olefin 
341 in 61% yield, together with enamine 342 (30%). The last stage involved removal of the extra 
carbon atom at C3 on ring D by decarbonylation of aldehyde 347. Toward this end, alkene 341 
was epoxidized using DMDO in the presence of BF3•Et2O. The resulting epoxide 343 was 
submitted to a regioselective Yamamoto rearrangement to lead to an allylic alcohol protected as 20 
an acetate 345 which was transposed by treatment with aqueous HCl to primary alcohol 346 then 
oxidized (Swern) into aldehyde 347 which, in the presence of Wilkinson’s catalyst, afforded the 
key Mori’s intermediate (–)-88. CET (–)-(1) could be likely obtained using Mori’s protocol85 in 
this way in 87% expected ee, twenty-three steps and 0.06-0.2% calculated OY from L-proline 
(S)-140. 25 
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Scheme 33. Formal synthesis of CET (–)-(1) by Hayes via Mori’s intermediate (–)-88 (2008) 
 
In their second formal synthesis of CET (–)-(1), an alkylidene carbene 1,5-CH insertion reaction 
was also used to establish the key tetrasubstituted stereocenter as previously described (Scheme 5 
34).142  
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Scheme 34. Formal asymmetric synthesis of CET (–)-(1) by Hayes (2008) 
 
However, as there is no additional carbon atom on the phosphorane 349, the previous tedious 
sequence to remove this very atom on ring D is no longer required (341 → (–)-88), seven steps, 5 
6.3 to 18.3% OY, scheme 33). The carbene precursor 350 was derived from N-Boc prolinal (S)-
348, obtained from L-proline (S)-140 in three steps and 94% yield.143 The resulting spirocyclic 
product 352 of carbene insertion was converted by Friedel–Crafts cyclization into Mori’s 
intermediate85 363 (R = Me) or (–)-88 (R = -CH2-) which were then transformed into CET (–)-
(1) following Mori’s procedure (Scheme 34).  10 
 
 73 
Ketone 350 was prepared by Wittig reaction of aldehyde 348 with phosporane 349. Protection of 
hydroxymethyl moiety with TBS was suitable for the carbene insertion, thus treatment of 350 
with lithium trimethylsilyldiazomethane gave the azaspirocycle 352 which was converted to 
NBoc spiroamine 355 by successive deprotection, oxidation and decarbonylation in good yield 
(63.2-84.6% from 352). Because racemization occurred at the tetrasubstituted stereocenter upon 5 
N-deprotection, compound 355 was first subjected to epoxidation. The epoxide 356 was not 
isolated and immediately treated with Lewis acid to provide 357 as the major product (2:1). 
Alcohol 357 was transformed into the CD amino alcohol 360 via tosylation, elimination with 
DBU to deliver the intermediate cyclopentene 186, and hydrolysis of the cyclic carbamate 
(scheme 34). Alkylation of 360 with the known nosylates 361 and 362 provided the ACD 10 
intermediate allylic alcohols 363 and (–)-364 which were subjected to Friedel–Crafts cyclization 
relying on Mori’s procedure85 (R = Me, PPA, 85%) or in Kuehne’s conditions94 with tin 
tetrachloride to give the intermediate (–)-88 although unexpectedly in medium yield. Herein, the 
relative configuration of the hydroxy group of 364 is very important. Compound 187, he 
diastereomer of 363, with the hydroxy group of opposite configuration, did not undergo the 15 
cyclisation reaction (see scheme 13). This sequence would allow access to CET (–)-(1) in 91% 
ee, in twenty-two steps and 0.3-0.4 % OY (R = Me) or in twenty steps and 0.4-0.5% OY (R = -
CH2-) from L-proline (S)-(140). 
 
3.3.3.4 Djaballah and Gin’s synthesis (2008) 20 
Three essential steps were used by Djaballah and Gin et al. for CET (–)-(1) synthesis (Scheme 
36).144 First, the nitrogen atom was introduced from the oxime 374 followed by Neber 
rearrangement. Secondly, construction of the benzazepine core relied on a strain-releasing 
rearrangement of N-vinyl-2-aryl aziridine 376 to 378. Eventually, assembly of the spiro-fused 
pyrrolidine core occurred via 1,3-dipolar cycloaddition of azomethine ylide derived from 25 
vinylogous amide 379. The chirality was introduced from the optically pure cyclopentenone 372 
substituted on C1 and C2 (CET (1) numbering), prefiguring the D ring. Compound 372 was 
prepared from D-ribofuranose (365). The isopropylidene group allowed stereocontrol, so that 
only one diastereomer 381 was obtained. 
Synthesis began by double protection of D-ribofuranose (365), then C1 olefination followed by 30 
Parikh–Doering oxidation furnished ketone 368  which was alkylated with with vinylmagnesium 
bromide to provide the allylic alcohol 369 (8:1 dr) (Scheme 35).  
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Scheme 35. Asymmetric synthesis of CET (–)-(1) by Djaballah and Gin: formation of ring D 
(2008) 
 
Cyclopentene 370 was prepared by a RCM (Grubbs II). Regioselective chloroselenylation of the 5 
alkene followed by selenide oxidation and elimination afforded the chlorocyclopentene and 
deprotection gave the vicinal diol 371. Eventually, the chiral β-chloroenone 372 [ten steps, 
42.2% OY from D-ribofuranose (365)] was obtained by periodate-mediated oxidative cleavage 
of the diol 371. 
 10 
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Scheme 36. Total asymmetric synthesis of CET (–)-(1) by Djaballah and Gin (2008) 
 
After the synthesis of 372 featuring the D ring of CET (1) (Scheme 35), the aziridine 375 was 
prepared in a few steps (Scheme 36). Condensation of ketone 373 with hydroxylamine 5 
chlorhydrate furnished oxime 374 which was reacted with LiAlH4 and diisopropylamine at 60 °C 
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affording the racemic aziridine 375 through a Neber-type reductive rearrangement. An addition–
elimination sequence starting with the addition of aziridine 375 onto β-chloro-enone 372 
furnished the N-vinyl aziridine 376 as a 1:1 diastereomeric mixture (Scheme 36). The dihydro-3-
benzazepine 378 was prepared by heating the aziridine 376 with Cs2CO3 which generated an 
efficient rearrangement via opening of the aziridine. Compound 378 was N-alkylated with 5 
TMSCH2I to give the tertiary vinylogous amide 379. O-Activation of vinylogous amide group in 
379 was carried out by pivaloyl triflate (generated in situ by combination of pivaloyl chloride 
and AgOTf), followed by desilylation with TBAT to give azomethine ylide 380. The dipolar 
cycloaddition with phenyl vinyl sulfone regioselectively afforded the spirofused pyrrolidine 381. 
In unexpected ways, only one diastereoisomer 381 was obtained, the C1–C2 isopropylideneketal 10 
was effective as a stereodirecting element. The desired R configuration at C5 was determined by 
single crystal X-ray diffraction analysis. Radical desulfurization followed by hydrolysis of 
pivalate and re-acylation with benzyl chloroformate led to 382. After diol deprotection, 
differentiation of the C1 and C2 oxygen substituents was achieved by using Boc2O and 
Yb(OTf)3 leading to a selective C1-O-carboxylation. The hydroxy group at C2 was oxidized to 15 
ketone using IBX. The enone 383 reacted with CrCl2 which induced reductive deoxygenation of 
the O-Boc group. Subsequent benzylcarbonate hydrogenolysis provided 
demethylcephalotaxinone (–)-12 (Weinreb’s intermediate83). Sequential methyl enol ether 
derivatization of the C2 ketone and stereoselective reduction at C3 with NaBH4 concluded the 
synthesis of (–)-CET (1) in twenty-four steps from D-ribofuranose (365) and 1.5% OY (ee n.d.). 20 
 
3.3.3.5 Ishibashi’s total synthesis (2008) 
In 2008, Ishibashi et al. reported an asymmetric synthesis145 based on a previous construction of 
the CET (1) skeleton using as characteristic feature an elegant radical cascade for the 
simultaneous construction of the B and C rings.146 Diethyl D-(–)-tartrate (384) was transformed 25 
into acetonide diol 385 whose tosylation and reaction with lithium phenylacetylide gave 
compound 387 (Scheme 37). After bromination, the acetonide group was removed and the 
intermediate bromodiol 388 was subjected to Bu3SnH-mediated radical cyclization to afford the 
cyclopentane diol 389 in 47% yield from 384 (eight steps). The two hydroxyl groups were 
protected and subsequent ozonolysis afforded the desired chiral cyclopentanone 390 which was 30 
condensed with amine 392 in the presence of Ti(Oi-Pr)4 to give an intermediary imine acylated 
with acryloyl chloride to afford enamide 393 in 50% yield (Scheme 37).  
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Scheme 37. Total asymmetric synthesis of CET (–)-(1) by Ishibashi (2008) 
 
Its treatment with Bu3SnH in the presence of 1,1′-azobiscyclohexanecarbonitrile (ACN) 
generated a radical cascade reaction building simultaneously the two rings B and C by a 7-endo 5 
and 5-endo selective cyclization; delivering the desired ABCD compound 394 in 27% yield. 
Deprotection of silylated hydroxyl groups by TBAF gave diol 395 which upon treatement with 
TFAA, DMSO and Et3N treatment afforded compound 396. Methylation of 394 and ultimate 
reduction using aluminum hydride96,132 led to CET (–)-(1) in 99.6% ee, ending the total 
asymmetric synthesis in 1.3% OY and seventeen steps from diethyl D-(–)-tartrate (384). 10 
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3.3.4 Chemical resolutions 
3.3.4.1 Nagasaka’s formal synthesis (1997) 
In 1997, Nagasaka et al. proposed the synthesis of CET (–)-(1) and ent-CET (+) (1) via 
resolution of chiral actetals of the spiro ketone ()-403 providing the C and D rings (Scheme 5 
38).133 This compound was used in the known procedure developed by Kuehne.94 Alkylation of 
the Stork enamine of cyclopentanone by methyl acrylate gave the cyclopentanone ester 399. 
After formation of the vinyl acetate 401, a nitro group (nitrogen atom precursor) was introduced 
using ammonium nitrate and trifluoroacetic anhydride to yield to the nitro compound 402. 
Reduction of the nitro group and in situ lactamization allowed formation of the spirolactam ()-10 
403. 
 
 
Scheme 38. Formal asymmetric synthesis of CET (–)-(1) by Nagasaka (1997) 
 15 
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Acetalization of ()-403 with (R,R)-2,3-butanediol 404 afforded two diastereoisomers (–)-405 
and (+)-406 which were easily separated by HPLC (100%). The optical purity was checked by 
chiral HPLC on compounds (–)-403 and (+)-403 obtained by hydrolysis of their respective 
acetals. Each enantiomer was confirmed to be enantiomerically pure. The two diastereoisomers 
(–)-405 and (+)-406 were alkylated with sulfonic ester 305 leading to Kuehne’s intermediates (–5 
)-306 and (+)-306. Synthesis of CET (–)-(1) and ent-CET (+) (1) in 99% estimated ee could be 
achieved employing Kuehne’s procedure94 in sixteen steps from cyclopentanone (397) and 5% 
calculated OY for each enantiomer. 
 
3.3.4.2 El Bialy’s formal synthesis 10 
In 2002, El Bialy et al.140 described a resolution of ACD spiroamine ()-408, an intermediate of 
Ishibashi and Ikeda’s syntheses130,137,138 of rac-CET ()-(1), with L-malic acid 409 (Scheme 39). 
Formal synthesis of CET (–)-(1) through Hanaoka’s intermediate (+)-14796 is described in 
section 3.3.2.2 (Scheme 32). 
 15 
 
Scheme 39. Formal asymmetric synthesis of CET (–)-(1) by El Bialy (2002) 
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Recrystallization of the ammonium malate of spiro compound (±)-408 gave the enantiomer (–)-
408 which could be converted to unnatural ent-CET (+)-(1). The mother liquor of malate salt 
afforded Ikeda’s intermediate (+)-408130 (yield not reported) which was protected and oxidized 
to the known ketone (+)-324, then transformed according to their sequence137,138 into 
intermediate (+)-149 in 89.3% ee measured by HPLC. Applying Hanaoka’s protocol would 5 
allow the synthesis of CET (–)-(1) in twenty steps and 89.3% estimated ee from piperonal (82).  
 
3.3.4.3 Stoltz’s formal syntheses (2007) 
Stoltz et al. developed a formal asymmetric synthesis of the two enantiomers of CET (1) and the 
first total synthesis of (–)-dupracine (16) using the spirocyclic amine ()-110 first used in their 10 
synthesis of rac-CET (±)-(1) (Scheme 5) to introduce CD rings.90 Compound ()-110 was 
coupled with the chiral non racemic hemiacetal 414 obtained by chemical resolution (Scheme 
40).90  
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Scheme 40. Asymmetric syntheses of (–)-drupacine (16) and formal asymmetric syntheses of 
CET (–)-(1) and ent-CET (+)-(1) by Stoltz (2007) 
 
3,4-Methylenedioxymandelic acid (R)-(413) (97.5% ee) obtained by chemical resolution with 5 
ephedrine (412) was protected as a 1,3-dioxolan-4-one prior to bromation then reduction to 
deliver compound 414 as a 1/1 mixture of diastereomers. This mixture reacted with spirocyclic 
amine ()-110 (see Scheme 5) under reductive amination conditions to give diastereomers 415 
and 416 in a 1:1 ratio, which were smoothly separated by chromatography. Both diastereomers 
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were submitted separately to Heck reaction conditions to produce benzazepines (+)-417 and (–)-
418. The benzylic hydroxy group was removed via an ionic deoxygenation procedure to afford 
the two enantiomers (+)-88 and (–)-88 of Mori’s intermediate,85 respectively. Formally, both 
enantiomers of CET (1) could be obtained in 97.5% ee over sixteen steps from β-ketoester 105, 
precursor of the CD unit (±)-110 (Scheme 5), in 0.2% OY for natural CET (–)-(1) and 0.7% OY 5 
for ent-CET (+)-(1). In their report, Stoltz et al. also completed the first asymmetric total 
synthesis of (–)-drupacine (16) in six steps from both anti and syn ABCD units (+)-417 (20.5% 
OY) and (–)-418 (19.3% OY) via a dynamic β-elimination/conjugate addition process of 
advanced intermediate a-hydroxyenones during acetalisation (Schemes 5 and 40). Starting from 
β-ketoester 105, the sequence consited in sixteen steps via spirocyclic enamine (±)-110, and 10 
delivered natural drupacine (–)-16 in a combined 1.34% OY. It is worthnoting that there remains 
only one total synthesis of racemic drupacine (±)-(16) disclosed by Fuchs in 1990.147 
 
3.3.5 Enzymatic resolution 
3.3.5.1 Mariano’s formal syntheses (2006) 15 
In 1994 and 1996 Mariano et al. reported a biomimetic synthesis of rac-CET ()-(1) by a 
transannular cyclisation.113,114 In 2006, they developed two formal syntheses of CET (–)-(1) 
based on photochemistry of pyrrolo-fused pyridinium perchlorate 421 leading to strained 
aziridine (±)-422.127,128 The first synthesis led to Mori’s intermediate85 430 (Scheme 41) and the 
second one to Suga and Yoshida’s intermediate86,87 (–)-102 (Scheme 42). 20 
The pyrrolo-fused pyridinium salt 421 was irradiated to give the tricyclic aziridine 422, its 
regioselective ring opening with acetic acid, amine protection with Boc, then protection of 
alcohol as acetic ester, at last deprotection of the Boc group with TFA led to meso spirocyclic 
aminodiester 425 in 5 steps and 38% OY. Desymmetrisation by enzymatic hydrolysis with 
electric eel acetyl cholinesterase (EEACE) afforded the unstable aminomonoalcohol 426 in the 25 
range of 80-90% ee which reacted with (3,4-dimethoxyphenyl)acetyl chloride (144) to furnish 
amido alcohol 427. To remove hydroxy group at C1, compound 427 was transformed into 
oxalate 428 which underwent radical reduction by treatment with AIBN/n-Bu3SnH generating 
the desired product 429 in a 10% yield along with the isomerized homoallylic alcohol 431 as the 
major product (65%). Mori’s intermediate 430 was obtained by reduction of 429 with LiAlH4. It 30 
was also obtained through a five step sequence (55% OY) from the rearranged homoallylic 
alcohol 431 involving alcohol deprotection and oxidation, α,β-unsaturated enone formation, then 
ketone and amide reduction. This formal synthesis could allow the synthesis of CET (–)-(1) in 
nineteen/twenty-three steps from 419 via ACD intermediate 430 with 0.1-0.5% expected OY 
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(brsm) and 51% estimated ee. This medium ee indicates that some epimerization occurred during 
transformation of spirocyclic compound 426 into ACD unit 430. 
 
 
Scheme 41. Formal asymmetric synthesis of CET (–)-(1) by Mariano via Mori’s intermediate 5 
430 (2006) 
 
The second approach by Mariano et al. described the synthesis of the ACD unit (–)-102 which is 
the key intermediate described by Suga and Yoshida86,87 (Scheme 42). The azaspiroalcohol 433 
was prepared earlier128 in enantiomerically pure form by using a sequential 10 
photocyclization/aziridine ring opening/enzymatic desymmetrization sequence with > 95% ee in 
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four steps and 19% OY from pyridinium salt 421. Radical reduction with tributyltin hydride and 
AIBN of the mixed oxalate gave the homoallylic ester 434. 
 
 
Scheme 42. Formal asymmetric synthesis of CET (–)-(1) by Mariano via Suga and Yoshida’s 5 
intermediate (–)-102 (2006) 
 
Hydrogenation with 10% Pd/C followed by hydrolysis with HCl of 434 generated the spirocyclic 
alkaloamine 435. Reaction with iodoarylacetyl chloride 432 furnished the spirocyclic 
amidoalcohol 436 which was transformed into the tosylate 437. Tosylate elimination with DBU 10 
afforded the unsaturated amide 438 which was reducted with aluminium trihydride to give the 
Suga and Yoshida intermediate (–)-102. This formal synthesis would give CET (–)-(1) in 95% 
expected ee over nineteen steps in 0.55% calculated OY from alcohol 419.  
 
3.3.5.2 Renaud’s formal synthesis (2012) 15 
In 2012, another formal synthesis of CET (–)-(1) was reported by Renaud.124 Unlike the 
alternative approach (see part 3.3.1.3, Scheme 27), an access to azaspiroamide 404 (Nagasaka’s 
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intermediate)133 was achieved through a stereoselective carboazidation sequence as the key step 
(Scheme 43). 
 
 
Scheme 43. Formal asymmetric synthesis of CET (–)-(1) via Nagasaka’s intermediate by 5 
Renaud (2012) 
 
In this synthesis, the silylated derivative (S)-439 (96.5% ee) was prepared from racemic 
cyclopentanol148 106 via enzymatic enantioselective acetylation with porcine-pancreas lipase 
(PPL). Carboazidation of (S)-439 afforded azido derivative 440 in 89% yield as a 1.2:1 mixture 10 
of isomers and their separation gave the major azido ester (1R,2S)-441 in 59% yield. Then, 
reductive lactamization, desilylation and oxidation gave Nagasaka intermediate (R)-403. 
Formally, this intermediate could be converted into CET (–)-(1) according to Kuehne94 and 
Nagasaka’s133 protocols, in eighteen steps, 1.8% calculated OY (alternatively nineteen steps and 
2.5% OY) and 96.5% estimated ee from methylene cyclopentanol 106 (see scheme 38). 15 
 
To conclude this part, it is interesting to compare the target intermediates in the formal syntheses 
of CET (1) as subtle changes in their structure may induce very different reactivities and OY of 
transformation into CET, either in its racemic form (Figure 18) or optically active one (Figure 
19). In addition, this schematic view shows in some ways the interconnections between the 20 
different approaches. 
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Figure 18 Target intermediates in the formal syntheses of (±)-CET (1). Names in boxes refer to 
a formal synthesis. 
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Figure 19 Target intermediates in the formal asymmetric syntheses of CET (1). Names in boxes 
refer to a formal synthesis. 
 
4. Synthesis and coupling of the side chains of Cephalotaxus esters 5 
Side chains of Cephalotaxus alkaloids are very important for the biological activity of the 
corresponding esters since it is well known that cephalotaxine itself does not exhibit interesting 
activity. They are characterized by a relatively simple structure with a chiral tertiary alcohol 
moiety. Nevertheless, coupling of the side chain to cephalotaxine remains an important challenge 
due to the steric strain exhibited at both the alcoholic function of cephalotaxine at C3 and the 10 
carboxylic function of the side chains which precluded a classical esterification process (Scheme 
44). Thus, in most of the syntheses of Cephalotaxus alkaloids, the esterification is done with a 
late, activated precursor of the side chain. It thus appeared that syntheses of the acidic side 
chains themselves are not useful processes to attain the Cephalotaxus esters. Nevertheless, 
numerous interesting syntheses of the acidic side chains have been reported. We will first report 15 
on the synthesis of the cephalotaxine esters and then on the synthesis of the side chains. In each 
part, syntheses will be presented in chronologic order.  
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4.1 Synthesis of cephalotaxine esters 
The previous review in this series2 reported more than fifteen syntheses of cephalotaxine’s 
esters. Due to the impossible coupling with the entire side chain 444, most of these syntheses 
dealed with the esterification of CET (1) with a precursor -keto acid 443 as shown in scheme 5 
44. Formation of the -keto ester 445 was followed by the introduction of the acetyl group 
through a Reformatsky reaction. Although this esterification/Reformatsky alkylation sequence is 
interesting, proceeded well and allowed the preparation of various harringtonines such as HT (3), 
HHT (2), deoxyHT (5) and so on, the sequence exhibits also a major drawback: the Reformatsky 
reaction on the prochiral keto ester part of 445 continuously gave a mixture of two epimers in a 10 
1/1 mixture leading thus to the loss of half part of the cephalotaxine. This major inconvenience 
was avoided in only two syntheses of HHT (2): the synthesis reported by Hudlicky149 (where the 
presence of the second keto group allowed a chelation with the Reformatsky reagent leading to 
the formation of a single stereomer) and the synthesis of Cheng150 (using a chiral sulfinyl ester). 
 15 
 
Scheme 44 Coupling of the side chain onto CET (–)-(1) 
 
Since the previous review in this series,2 only four articles dealing with syntheses of CET esters 
have been published. 20 
 
4.1.1 Robin’s Synthesis of Semisynthetic HHT (1999) 
The first one by Robin21 in 1999 is quite interesting in opening new routes to these alkaloids. 
This strategy was based on the esterification of CET (1) with a cyclic precursor of the side chain, 
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the tetrahydropyran rac-449 (Scheme 45) which was easily prepared in 4 steps from α-ketoester 
446.  
 
 
Scheme 45 Hemisynthesis of ssHHT (2) by Robin (1999) 5 
 
Keto ester 446 was treated with the lithium methyl acetate to give diester 447 which was fully 
saponified and then cyclized with formic acid to the diacid 448. The latter was selectively 
monoesterified with BF3•MeOH to furnish the acid ester 449. CET (1) was coupled with rac-449 
using DCC or mixed anhydride method, but once again the obtained ester was a mixture of two 10 
epimers in a 6/4 ratio and had to be separated by chromatography. While the authors showed that 
highly enantiomerically pure HHT (2) (99.8% ee) could be obtained in a large scale process, they 
also developed a diastereoselective sequence. For this purpose, rac-449 was resolved through its 
quinine ester. Eventually, coupling of CET (–)-(1) and (–)-449 gave anhydroHHT (450) which 
can also be hydrolyzed to enantiopure HHT (–)-(2). This methodology using tetrahydropyran 15 
449 was patented in 2005 and applied to synthetize various analogs.151 
 
4.1.2. Marguerit’s Synthesis of [14C]-Labelled HHT (2015) 
In 2015, Marguerit et al. achieved the first radiolabelled synthesis of HHT (–)-(2) (Scheme 
46).152 This synthetic process enabled the production of Good Manufacturing Practice (GMP) 20 
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compliant [14C]-HHT (–)-(2). This 14C-labelled compound was used in a human mass balance 
study that was a post-approval commitment to the U.S. FDA. 
 
 
Scheme 46 Synthesis of [14C]-labelled HHT (–)-(2) by Marguerit (2015) 5 
 
[14C]-Labelled HHT ([14C]-(–)-2) was obtained from [14C]-labelled CET ([14C]-(–)-(1)) 
according to an efficient semi-synthesis described in 1999 using enantiopure Robin’s acid 449.21 
The synthetic strategy to obtain [14C]-CET (–)-(1) is based on the coupling of [14C]-labelled 
tosylate intermediate [14C]-305 with enantiopure spirolactam (–)-304 developed by Royer132 for 10 
the synthesis of CET (–)-(1). For their purpose, introduction of the [14C] label was done by 
reaction of benzyl chloride intermediate 451 with potassium [14C]-cyanide, a readily available 
source of carbon-14, yielding compound [14C]-452, followed by transformation into [14C]-
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tosylate 305. This convergent approach proceeds via two key unlabeled intermediates 304 and 
451 synthesized in parallel. Alkylation of spirolactam (–)-304 with the tosylate [14C]-305 
afforded ACD unit [14C]-(–)-306 which was transformed into radiolabelled [14C]-CET (–)-(1). 
Eventually, [14C]-HHT (–)-(2) was obtained using Robin’s protocol by coupling [14C]-CET (–)-
(1) with Robin’s acid (–)-(449) and hydrolysis of the side chain of intermediate anhydroHT [14C] 5 
(–)-(450).21 From piperonyl alcohol obtained from piperonal (82), the seventeen steps sequence 
provided after preparative reverse phase HPLC a 100% enantiopure product with a 
radiochemical purity of 98.9% and a chemical purity of 98.5% in 4.475% OY. 
4.1.3. Gin’s Synthesis of DeoxyHT (2006) 
The synthesis of deoxyHT (–)-(5) reported by Gin in 2006153 was the most recent and also the 10 
most efficient method of synthesis of CET esters. This synthesis was based on the esterification 
of a cyclic acid, namely the β-lactone 456 obtained in a non-racemic form through an efficient 
sequence (Scheme 47). It started with acetal derivatization of D-malic acid D-(409) with 
pivalaldehyde to give dioxolanone 453. Diastereoselective alkylation of dioxolanone 453 with 
prenyl bromide was accomplished after deprotonation with LiHMDS to give the prenylated 15 
dioxolanone 454 in 66% yield. This sequence allowed the introduction of the chiral tertiary 
alcohol with complete diastereoselectivity following the studies of D. Seebach126 and Tietze (see 
Scheme 51).154 Transesterification with acetal cleavage of 454 using benzyl alcoholate provided 
the tertiary alcohol 455 which was cyclized to the β-lactone followed by hydrogenolysis and 
hydrogenation to give the acid 456. Activation of the carboxylic function with 2,4,6-20 
trichlorobenzoyl chloride allowed the acylation of CET (–)-(1) followed by transformation into 
deoxyHT (–)-(5) upon methanolysis. 
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Scheme 47 Synthesis of deoxyHT (–)-(5) by Gin (2006) 
4.1.4. Djaballah and Gin’s Synthesis of AnhydroHT, HHT and HomodeoxyHT 
(2008) 
Djaballah, Gin and coworkers extended this study to the syntheses of others CET esters like 5 
HHT (–)-(2), homodeoxyHT (–)-(22) and anhydroHT (–)-(20).144 Preparation of anhydroHT (–)-
(20) (Scheme 48) involved the intermediate (R)-455 of the previous synthesis153 (see Scheme 47) 
which, after transformation into the corresponding methyl ester, was cyclized to tetrahydrofuran 
457 through alkoxymercuration. Deprotection of the benzyl ester and activation as a mixed 
anhydride (Yamaguchi’s reagent) allowed the coupling with CET (–)-(1) to give anhydroHT (–)-10 
(20) in excellent yield. 
 
 
Scheme 48 Synthesis of anhydroHT (–)-(20) by Djaballah and Gin (2008) 
 15 
Preparation of HHT (–)-(2) and homodeoxyHT (–)-(22) (Scheme 49) involved a synthesis based 
on β-lactone 458 obtained through a sequence which mimicked the synthesis described in 
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Scheme 47. A cross metathesis provided the disubstituted alkene 460 in 61% yield (a dimeric 
bislactone was also formed). After cleavage of the benzyl ester, the activation of the carboxyl 
group (Yamaguchi’s reagent) allowed the coupling with CET (–)-(1) to furnish 461 which was 
transformed into 462 upon methanolysis. Preparation of each natural compound HHT (–)-(2) and 
homodeoxyHT (–)-(22) from this common intermediate is interesting. When allyl benzyl ether 5 
462 was treated with H2 (Pd/C) in MeOH followed by addition of AcOH at the last stage of the 
reaction, HHT (–)-(2) was isolated in 79% yield. On the other hand, 462 gave homodeoxyHT (–
)-(22) in 69% yield when submitted to Pd/C catalyzed hydrogenation in glacial AcOH. 
 
 10 
Scheme 49 Synthesis of HHT (–)-(2) and homodeoxyHT (–)-(22) by Djaballah and Gin (2008) 
 
4.2 Synthesis of Side Chains of Cephalotaxus Esters 
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Though it has been clearly shown that coupling of CET (1) with entire side chains was not 
possible, syntheses of these side chains have been continuously prolific. All the syntheses 
reported since 1998 were asymmetric and are of interest due to their diversity and originality. 
Some of them included the preparation of already described intermediates in the synthesis of 
Cephalotaxus esters and then could be considered as formal syntheses of the natural products.  5 
4.2.1 Dumas and d’Angelo’s Synthesis (2001) 
The first asymmetric synthesis of the side chain ester 473 of HHT (2) was reported by Dumas 
and d’Angelo.155,156 In this work, the formation of the chiral tertiary alcohol center was 
accomplished in a highly diastereoselective manner in an early stage of the sequence. The 
synthesis started with the preparation of the known chiral imine 465 (Scheme 50) which was 10 
subjected to a Michael reaction with acetoxyacrylonitrile (466), an equivalent of the acid side 
chain. The adduct 467 was proved to be stereochemically homogeneous and was hydrolyzed 
without purification to give the more stable ketone (R,R)-468. The keto group was protected as a 
dioxolane and the potential aldehyde function was directly transformed into the ester 469 upon 
treatment with MnO2 in MeOH in the presence of NaCN. The ketal of ester 469 was cleaved 15 
using CeCl3•7H2O and NaI and the so-formed keto group was converted to the silylvinyl ether 
470. Ozonolysis of 470 gave the sensitive aldehyde 471. Addition of MeMgBr to the crude 
aldehyde and esterification of the acid furnished alcohol 472. Oxidation of the alcohol 472 to a 
methylketone followed by new addition of MeMgBr gave the tertiary alcohol which eventually 
upon hydrogenolysis led to (R)-methyl 3,7-dihydroxy-3-methylcarbonyl-7-methoxyoctanoate 20 
(473), the methyl derivative of HHT side chain. 
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Scheme 50 Synthesis of HHT side chain (R)-473 by Dumas and d’Angelo (2001) 
 
4.2.2 Tietze’s Synthesis (2005) 
In 2005, Tietze reported the preparation of the chiral side chain acids 480–483 of deoxyHT (5), 5 
homodeoxyHT (22), nordeoxyHT (21) and neoHT (19), respectively (Scheme 51)154 based on 
Seebach’s procedure for the alkylation of D-malic acid with self-regeneration of stereogenic 
centers.126 The strategy was used later by Gin for the preparation of CET esters.153 The 
dioxolanone 453 prepared from D-malic acid (D-409) was treated with 2 equiv. of LiHMDS 
followed by bromoallyl derivatives to give allylated dioxolanones 474–476 in high yield and 10 
diastereoselectivity. Upon hydrogenation on PtO2, these compounds furnished dioxolanones 
477–479 whose acid hydrolysis permitted the isolation of 480–482, side chains of deoxyHT (5), 
homodeoxyHT (22) and nordeoxyHT (21), respectively. When 453 was alkylated with benzyl 
bromide, the same sequence allowed the obtention of 483, the side chain of neoHT (19). 
 15 
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Scheme 51 Synthesis of side chain acids of harringtonines by Tietze (2005) 
 
4.2.3 Russel’s synthesis (2006) 
An original approach was reported by Russel et al. in 2006.157 The synthesis started with 5 
chiral non-racemic aldehydes (R)-489 or (R)-491 (Scheme 52) whose preparation in large scale 
was reported by the authors from citric acid (484) and resolution of dioxolanone (±)-487.158  
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Scheme 52 Synthesis of harringtonines’ side chains by Russel (2006) 
 
Three compounds were described in this study: (R)-493 and (R)-496, the anhydroHT and 
HHT’s side chains respectively, and (R)-449, the intermediate used by Robin for the synthesis of 5 
HHT (2) (see Scheme 46) thus representing a formal synthesis of HHT (2). Dioxolanone (R)-487 
was obtained in three steps and resolution in 11.4% OY from citric acid (484).158 The acid 
function of (R)-487 was selectively reduced under Rosenmund conditions to aldehyde which 
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reacted with a vinyl Grignard reagent (491 or 494) to give lactones 492 or 495. Lactone 492 was 
reduced with rearrangement to (R)-493, the side chain of anhydroHT (20) obtained in 2.3% OY 
(nine steps from 484), while reduction of lactone 495 gave (R)-496, the side chain of 
homodeoxyHT (22) in 4.7% OY over eight steps from 484. The same sequence was applied to 
aldehyde (R)-490 allowing preparation of Robin’s intermediate (R)-449 useful for the synthesis 5 
of harringtonines, in 3.3% OY and twelve steps from citric acid (484). 
 
4.2.4 Royer’s synthesis (2009) 
Several Cephalotaxus alkaloid side chains were prepared by Royer through a rapid synthesis 
(four–five steps).159 The central point of this synthesis is a chiral non-racemic epoxide 498 10 
(Scheme 53). Side chains were obtained upon epoxide ring-opening with appropriate 
nucleophiles. On the other hand, it was postulated that this epoxide could be a good candidate for 
esterification with CET (1) while no report of such coupling was available. The diester 501, 
easily obtained from commercially available monomethyl itaconate (499) and methyl mandelate 
(500), was epoxydized with mCPBA to give a 1/1 diastereomeric mixture of 502 in good yield. 15 
Flash chromatography permitted the isolation of (+)-502 with the required (S,S) absolute 
configuration. Then, epoxide (+)-502 was reacted with various organocuprates to give 
compounds 503–507. Hydrogenolysis of 503–507 allowed the obtention of (R)-508, (R)-496, 
(R)-509, side chains of deoxyHT (5), homodeoxyHT (22) and neoHT (19), respectively and 
analog (R)-510 in 12.2-17.8% OY. Hydroxymercuration of 507 followed by spontaneous 20 
cyclization then hydrogenolysis of the chiral appendage delivered (R)-494, the side chain of 
anhydroHT (20) in 10.8% OY.  
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Scheme 53 Synthesis of harringtonines’ side chains by Royer (2009) 
 
4.2.5 Yang’s synthesis (2013) 
In 2013, Yang reported the [2,3]-Meisenheimer rearrangement as a general strategy for the 5 
construction of chiral tertiary alcohols.160 As an illustration of this method, the synthesis of HT 
and HHT’s side chains is shown in Scheme 54. The synthesis began with known N-Boc ester (S)-
512 of L-aspartic acid obtained through a two-step process (94%). The gem-dimethyl group was 
first installed by a Grignard reaction to give 513 which was transformed into the lactol 514 by 
IBX oxidation and concomitant cyclization. The Wittig reaction with phosphorane 515 followed 10 
by deprotection and N-bisbenzylation of the amino group furnished key allylamine (S)-516. The 
Meisenheimer rearrangement occurred upon treatment with mCPBA on the latter to give 
hydroxylamine 517. This compound led to 518 upon treatment with H2 on catalytic Pd/C via 
double bond saturation then N-O bond cleavage. Eventually, upon oxidation of 518 the HHT’s 
side chain acid (R)-481 was obtained whose methylation yielded the corresponding dimethyl 15 
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ester (R)-473. Its optical rotation indicated a perfect stereochemical outcome of the 
rearrangement. A similar process allowed synthesis of a cyclic form of the HT’s side chain. 
Starting from L-threonine (519), amino alkene 520 was prepared in seven steps. The 
Meisenheimer rearrangement occurred upon treating 520 with mCPBA to give the sensitive 
hydroxylamine 521. Six steps were then needed to obtain (R)-522, a cyclic form of the HT’s side 5 
chain acid. 
  
Scheme 54 Synthesis of harringtonines’ side chains by Yang (2013) 
 10 
These authors patented the preparation of HHT’s side chain acid (R)-481 by this methodology.161 
Through the same sequence, Yang and coworkers have also described the synthesis of the diacid 
side chain of deoxyHT (5) and homodeoxyHT (22) starting from L-valine and L-leucine 
respectively.162 
 15 
4.2.6 Hung’s synthesis (2014) 
Hung et al. 163 recently reported the synthesis of the esters (473) and (524) of the side chains 
of HHT (2) and homodeoxyHT (22), respectively, by using Tietze154 and Gin’s methods144 
(Scheme 55). Allylation of 453 (see Scheme 51), esterification then cross metathesis (see 
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Scheme 49) with allyl alcohol 524 allowed the preparation of dioxolanone 523.The latter was 
subjected to different hydrogenation conditions to give after methanolysis (R)-473 or (R)-526, 
side chains’ esters of HHT (2) and homodeoxyHT (22). 
 
 5 
Scheme 55 Synthesis of HHT and homodeoxyHT side chains by Hung (2014) 
 4.2.7 Mac’s synthesis 
In 2016, Tietze’s method154 (see Scheme 51) was also used by Mac et al. for the synthesis of a 
series of side chains analogs of HHT (2) (Scheme 56).164 The dioxolanone 453 was 
diastereoselectively allylated to furnish compound (R,R)-523. A Mizoroki–Heck type reaction 10 
with various phenylboronic acid derivatives followed by hydrogenation and methanolysis gave 
arylated ester chain analogs 527a–h of HHT (2) in moderate to good yield. 
 
 
Scheme 56 Synthesis of HHT side chain’s analogs by Mac (2016) 15 
 
5. Synthetic Analogs and their Biological Properties 
The synthesis of analogs of bioactive natural products remains a broad area of research that can 
lead to very interesting new structures with improved activity. In the case of Cephalotaxus 
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alkaloids, the exchange of the ester side chain appears to be the simplest way to access analogs 
and this strategy has been used and described in some patents. The structural modifications of 
the cephalotaxine core seem more difficult but have been also scarcely addressed giving rise to 
interesting compounds and synthetic pathways. We will describe below the most significant 
reports. Works describing attempts to synthesize CET (1) or the preparation of compounds with 5 
a passing structural resemblance will not be considered in this section. 
5.1. Cephalotaxine analogs 
 5.1.1. Tietze’s CET analogs (2000, 2007) 
Since 1997, several reports on the synthesis of CET’s analogs have appeared. Tietze at al. in 
2000165165 described the preparation of four analogs rac-532–535. For these compounds, 10 
variation of the size of the different rings B and C of the polycyclic core of CET (1) and ring A 
substitution was explored. These authors used their strategy developped for the synthesis of the 
natural product (Scheme 57). 
 
 15 
Scheme 57 Synthesis of CETanalogs by Tietze (2000) 
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Compounds 530a–h, with various chain lengths and ring sizes, were easily prepared in a few 
steps by alkylation of 84 and 528a–c with 81and 529a–c using a standard SN reaction. 
Compounds 530a–h were then submitted to a Pd-catalyzed Tsuji–Trost cyclization to give 531a–
c,e,f,h in satisfactory yields (compounds 530d,g did not cyclize under these conditions). The 5 
final Heck cyclization required the use of Hermann–Beller’s palladacycle 87 and allowed the 
preparation of compounds 532–535 and 88. In this study, the final compounds required further 
reactions to install at least an alcoholic function on ring D to allow the coupling with side chains. 
This drawback was eliminated in a following study published in 2007 by the same authors.166 
Furthermore, Cephalotaxus esters analogs were prepared by coupling the CET analogs with 10 
homodeoxyHT side chain (Scheme 58). The synthesis was now based on a domino reaction 
giving a rapid and efficient access to ACD compounds 538 from amines 536, 528a, 84 and 
cyclopentenone ester 537. 
 
 15 
Scheme 58 Synthesis of deoxyHT analogs by Tietze (2007) 
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The Pd-catalyzed reaction of 538a–c allowed the formation of the tetracycle 539a–c. While 
LiAlH4 reduction of 539a–c gave efficient access to amino alcohols 540a–c which are analogs of   
CET (1), these compounds did not couple with an activated form of the side chain of 
homodeoxyHT (22). In contrast, it was observed that NaBH4 reduction of 539b,c gave the 
amidoalcohols rac-541b,c which allowed coupling with the imidazolide 542 of homodeoxyHT 5 
side chain furnishing after further reduction the esters 543b,c which are analogs of 
homodeoxyHT(22). It should be noted that the presented synthesis is racemic and that optically 
pure side chains were used leading to a mixture of two diastereomers which were separated. 
 
5.1.2. Bubnov’s CET analogs (2005-2010) 10 
In 2005, Bubnov et al.167 published the synthesis of compound rac-548 exhibiting some 
structural analogies to CET (1) with ring B and D being bridged and not fused (Scheme 59). The 
synthetic strategy was simple and started with 2-pyrrolidone (181) which was diallylated, N N-
protected and transformed into spiro-pyrrolidine 545 through ring closure metathesis. 
Condensation of 545 with acyl chloride 546 gave access to 547 which was transformed to the 15 
desired product rac-548 by Heck cyclisation. The same type of work was pursued by the authors 
in 2010168 allowing the preparation of new products 549–552. 
 
 
Scheme 59 CET’s analog synthesized by Bubnov (2005-2010) 20 
 
5.1.3. Royer’s CET analogs (2004-2010) 
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Exploiting their early developed strategy, Royer et al. (see Scheme 29) prepared three C7-
alkylated CET analogs from chiral non-racemic Kuehne’s intermediates 123 and 553 (Scheme 
60).132 Alkylation was carried out on protected lactam 554 through deprotonation using sec-BuLi 
and addition of MeI, BuI, or PhCH2Br to provide diastereomeric alkylated lactams 555 and 556 
in a 4/1 ratio. The new chiral center of the major isomer has the (S)-configuration. 5 
Transformation of acetonide 555 led to alkylated cephalotaxines 557–559 in a four-step 
sequence in 15-28% OY. 
 
 
Scheme 60 Synthesis of CET alkylated analogs by Royer (2004) 10 
 
In 2010, these authors reported a different type of cephalotaxine analogs in which the A ring 
was changed for a phenyl or a naphthyl group (Scheme 61) using the same strategy as for CET’s 
synthesis (see Scheme 34).169  
 15 
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Scheme 61 Synthesis of CET “A” analogs by Royer (2010) 
 
N-alkylation of the spirolactam (–)-304 with the appropriate arylethyl derivative 560a,b gave 
561a,b. The end of the synthesis paralleled those of the cephalotaxine synthesis: functional 5 
group manipulations of 561a,b led to 562a,b. These spiro compounds 562a,b were cyclized to 
the ABCD compounds 563a,b which were eventually transformed to the phenyl 564 and 
naphthyl 565 CET analogs. 
 
5.1.4. Chandrasekhar’s CET analogs (2016) 10 
In 2016, Chandrasekhar et al. used their aryne insertion methodology to synthetize three CET 
analog intermediates (Scheme 62).120 In these compounds 570–572, the A ring is changed for a 
phenyl, dimethylphenyl or dimethoxyphenyl ring. 
 
 15 
Scheme 62 Formal synthesis of CET “A analogs” by Chandrasekhar (2016) 
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To conclude, it is noteworthy that if several analogs of CET (1) have been designed and 
synthesized, they have been coupled with side chains for only two products (in two reports), 
although their biological activity was not reported. 
 5 
5.2 Cephalotaxus esters with side chain analogs 
5.2.1. Robin’s analogs (2002-2004) 
Robin et al. patented Cephalotaxus esters 575 with various side chains.170,171 They were prepared 
by transesterification of HHT (2) (path B) or ring-opening of intermediate 574 (Scheme 63) with 
yields between 21 to 82%. For example, HHT (2) dissolved in (E,E)-hexa-2,4-dien-1-ol was 10 
treated with sodium hydride to yield synthetic CET ester 575a in 30% yield. This compound was 
the most active of the tested analogs in this study with nanomolar IC50 (3.5 ng/mL) while HHT 
(2) was less potent (IC50 14 ng/mL). 
 
 15 
Scheme 63 Robin synthesis of HHT analogs at the side chain  
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Scheme 63 (continued) Robin synthesis of HHT analogs at the side chain  
 
Analogs 576 of HT (3), 579 of drupangtonine (33) and 577 and 578 of HHT (2) were also 
synthetized by conventional methods (Figure 20). 5 
 
 
Figure 20 Harringtonines analogs at the side chain (HHT (top) and drupangtonine (bottom) 
analogs) synthesized by Robin (2002-2004) 
 10 
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This work delineated the ester groups that reduced the cytotoxic activity against the K562 
leukemic cell line (Table 11). Nevertheless, a few ones gave rise to improved activity as esters 
575a (n-hexadienyl), 575b (n-hexyl), 575s (n-hepthyl), 575v (4-methylbenzyl), 575w (3-
methylbenzyl), 575af (2-methylthiophene), 575ag (2-methylfurane). 
 5 
 
 
5.2.2 Djaballah & Gin’s analogs (2008) 
In 2008, Djaballah and Gin synthesized four CET-ester analogs, benzyldehydroHHT 580, 
bisnorhomodeoxyHT 581, bisnorhomodeoxyHT β-lactone 582 and deoxyHT β-lactone 583 10 
(Figure 21), using the protocol described in section 4.1.3 (Scheme 47).144 They exemplified up to 
forty three Cephalotaxus esters analogs, some of which being dimers of CET (1) linked by a 
central oxygenated chain by the C3 hydroxyl group.172 
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Figure 21 Djaballah and Gin’s CET-ester analogs (2009) 
 
These harringtonine structural analogs were tested against human hematopoietic and solid 
tumor cell lines (Tables 12 and 13), and compared to HHT (2), deoxyHT (5), homodeoxyHT 5 
(22) and anhydroHT (20) which are among the most active Cephalotaxus alkaloid esters. 
 
 
 
HHT (2) shows decreased activity by a factor of 125 (resistance index (RI) = 125), whereas 10 
esters deoxyHT 5, homodeoxyHT (22), benzyldehydroHHT (580), and bisnordeoxyHT (581) 
have much lower RI of 11, 3, 19, and 12 respectively, indicating that they are significantly less 
sensitive to MDR and tumor cell lines can therefore be considered to be sensitive to these 
products. One possible explanation for the greater susceptibility of HHT (2) to MDR is its low 
lipophilicity due to the structure of the side chain, making it a good substrate for the efflux 15 
pumps. 
Compounds having a ClogP value greater than 1.2 generally lead to a low susceptibility 
to MDR (i.e., IR = 19 to the esters 5, 22, 580, and 581). The exception is HHT (2), which has a 
relatively low value of cLogP (0.95, relatively polar) reflecting its susceptibility to MDR (i.e., IR 
= 125). All these compounds show a broad spectrum of cytotoxic activity, with the exception of 20 
the retinoblastoma cell line Y79 (Table 13), which can be attributed to the overexpression of the 
MDR gene in this line. 
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5.2.3 Lai’s analogs (2013) 
In 2013, Lai et al. applied for two patents, one on preparation of aminated HHT derivatives 
584173 (Figure 20) and the other on acylated HHT derivatives 585 and 586 (Figure 22).174 5 
Compounds 584a-w were prepared from HHT (2) via saponification of the methyl ester to HHT 
acid (31) and amidation with various amines R1R2NH in the presence of HATU/DIPEA in 6 to 
44% yield (Figure 22). Groups R1 and R2 could be H, C1–18 alkyl, C2–18 alkenyl, C2–18 alkynyl, 
C3–7 cycloalkyl or cycloalkenyl, aryl, heteroaryl or saturated heterocyclic ring systems etc. 
Twenty three HHT aza analogs were tested against human hematopoietic and solid tumor cell 10 
lines (Table 14), and compared to HHT (2). Analogs 584c, f, n, o, and u were inactive (IC50 ≥ 16 
µg/mL). Compound 584b and 584i were the most active of the tested analogs in this study with 
nanomolar IC50 (up to 42 and 57 ng/mL) while HHT (2) was more potent (IC50 6 ng/mL). The 
most promising analogs were tested against HeLa (cervical), CaES-17 (esophageal), CNE 
(nasopharyngeal), Hep2 (liver), MGC 803 (gastric), PC-3 (prostate) and SK-OV-3 (ovary) 15 
human cancer cell lines (Tables 15 and 16), and however, none of these compounds were more 
active than HHT (2). 
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Figure 22 Lai’s HHT (2) aza analogs (2013) 
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Monoacyl-HHT analogs 585a–i and diacyl-HHT analogs 586a–f were prepared with activated 
HHT and carboxylic acids, anhydrides or acyl chlorides via esterification in 6–99% yield (Figure 
23). 5 
 
 
Figure 23 Lai’s HHT (2) acylated analogs (2013) 
 
The acylated analogs were compared to HHT (2) and tested against against human hematopoietic 10 
(Table 17) and solid tumor cell lines (Tables 18–19) including K562/adr (myelogenous leukemia 
resistant to Doxorubicin), Kasumi-1 (acute myeloid leukemia), NB4 (acute promyelocytic 
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leukemia), Jurkat (childhood T acute lymphoblastic leukemia), H9 (cutaneous T-cell lymphoma), 
RPMI8226 (Plasma cell myeloma), Huh7 (hepatoma), A549 (lung adenocarcinoma), PANC-1 
(exocrine pancreas carcinoma), Becap37 (breast), MG63 (osteosarcoma), RKO (colon), U87 MG 
(glioma), HeLa (cervical), CaES-17 (esophageal), CNE (nasopharyngeal), Hep2 (liver), PC-3 
(prostate), SK-OV-3 (ovary) and MGC 803 (gastric) cell lines. Contrary to aza analogs 584 and 5 
diacylated analogs 586a–f, the monoacetate analog 585a was at least as effective as HHT (2) 
against all the investigated cell lines (Tables 17–19). Compound 585f and 585g were more 
potent than HHT (2) against eighteen and seventeen over the twenty cell lines tested, 
respectively. 
 10 
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 5 
In conclusion, the study of many syntheses of CET (1) published to date can draw a number of 
conclusions about the key points of its structure and the way chemists have overcome the 
problems posed by its synthesis. The formation of the B ring often remains a crucial point in 
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building the CET skeleton. The C4–C13 disconnection remains by far the most studied (>thirty 
syntheses of fifty). The cyclization reactions used (electrophilic aromatic substitutions, 
organometallic coupling ...) perform generally with good yields, but seem susceptible to 
cyclization intermediates and electronic richness of the aromatic ring. This disconnection is also 
extremely interesting from a stereochemical point of view providing the correct relative 5 
configuration at C4 and C5, avoiding difficult separations. Other disconnections do not always 
give such good results and are not completely diastereoselective. The formation of the spiro CD 
system is also a key point in these syntheses; in fact, the control of center C5 at the start of 
synthesis greatly simplified stereocontrolled strategies and enabled enantioselective approach to 
CET (1) by asymmetric synthesis of the CD system. Subsequent stereoinduction of the C5 center 10 
on C4 center and C4 center on the C3 center facilitate the production of optically active CET (1). 
However, the operating conditions used after the synthesis of the spiro system must be chosen 
carefully because of the risk of racemization of CET (1) and certain synthetic intermediates by 
breaking the N9–C5 bond (See Figures 18 and 19, the conversion of Mori’s intermediates (±)-88 
and (–)-88). Last but not least, from an industrial point of view, initially the Merck Group took 15 
over the Weinreb racemic synthesis improving performance (11.7% by eliminating some 
purification steps). The optically active CET (1) in its natural configuration may be obtained by 
resolution of racemic cephalotaxine rac-CET (±)-(1) with tartaric acid, by incorporation of chiral 
sources, or by enantioselective synthesis. The high purity HHT (2) used for clinical trials was 
obtained by extraction (NCI batches) and by semisynthesis (ssHHT) from natural CET (1) then 20 
purified by HPLC to remove impurities and minor diastereoisomers first by the French 
compangy Oncopharm SA later based in Houston (USA). A number of HHT analogs were 
prepared; however only the monoacylated analogs 585a, 585f and 585g showed slight increase 
in activity agains both hematopoietic and solid caner cell lines. The main advantage was to 
prepare hydrosoluble stable forms. 25 
 
6. Pharmacology and Clinical Studies 
6.1 Cellular pharmacology  
6.1.1 Molecular Mechanism of action of HHT 
Molecules like HHT (2) which works on several targets are increasingly attractive. Protein 30 
synthesis inhibitors could affect the translation of mRNA into proteins at several different stages, 
such as, initiation, elongation and termination as illustrated in Figure 24. The main activity of 
HHT (2) is blocking protein synthesis during the initiation step. Mainly, it inhibits the synthesis 
of short lived proteins175 by binding to the A-site cleft of tRNA A-site in the peptidyl-transferase 
center of the ribosome. The aminoacyl-tRNAs binding site is universally conserved over 35 
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prokaryotes and eukaryotes. The Nobel Prize in Chemistry 2009 was awarded jointly to 
Ramakrishnan, Steitz and Yonath "for studies of the structure and function of the ribosome". 
They have all generated 3D models that have shown how different antibiotics, including HHT 
(2),176 bind to the ribosome. Also, they demonstrated by X-ray (at high resolution up to 2.9 Å) 
the crystals of the 80S ribosome in complexes with twelve eukaryote-specific inhibitors and four 5 
broad-spectrum inhibitors in Saccharomyces cerevisiae.177  
 
  
 
Figure 24: Simplified diagram of protein synthesis showing the A site where HHT binds to 10 
inhibit protein synthesis.178 In the cytoplasm of the cells, ribosomes (green) bind to the 
messenger RNA (mRNA) containing the code translated from the switched on genes into the 
DNA. The twenty different amino acids carried by transfer RNA (tRNA) are recruited according 
to a three nuclear base code into the ribosome A site. The protein chain elongation includes the 
aminoacyl tRNA entry, its proofreading, the peptidyl transfer, and the ribosomal translocation 15 
along the tRNA chain. The cartoon on the right explains how HHT (2) inhibits protein synthesis 
through inhibition of initiation elongation step. 
 
Both the ring system and the tail of HHT (2) participate in interactions with the ribosome that 
contribute to drug binding. HHT (2) interaction with the ribosome is stabilized by hydrophobic 20 
interactions and hydrogen bonds (Figure 25). Its six-membered aromatic ring stacks on the base 
of Cytosine 2452 for H. marismortui (2487 for E. coli), and it fills the A-site cleft completely, 
the five-membered dioxolane ring attached to it. When HHT (2) is bound to the ribosome, 73% 
of its surface area becomes water inaccessible. The tertiary amine of HHT (2), which is 
protonated at neutral pH, establishes hydrogen bond with the O2 of Cytosine 2452 H. 25 
marismortui (2487 for E.coli). The hydroxyl group at the side chain forms a hydrogen bonding to 
the O6 of Guanine 2058 H. marismortui (2099 for E. coli) via intermediate water molecule, and 
the carbonyl group at the other end of the side chain establishes hydrogen bond with the N2 of 
Guanine 2061 for H. marismortui (2102 for E. coli). The binding of HHT (2) to the large 
ribosomal subunit induces several conformational changes. The most powerful of them is 30 
roughly 50 ° reorientation of the base of Uracil 2506 for H. marismortui (2541 for E. coli), 
which enables it to stack on top of the drug. In the drug complex, Uracil 2506 for H. marismortui 
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(2541 for E. coli) forms a symmetric O4–N3/N3–O4 base pair with Uracil 2585 for H. 
marismortui (2620 for E. coli). In all other crystal structures of the large ribosomal subunit from 
H. marismortui, Uracil 2506 for H. marismortui (2541 for E. coli) forms a Guanine-Uracil base 
pair with G2583(2618). A number of more subtle conformational changes are seen in the A-site 
cleft region; C2452 of H. marismortui (2487 for E. coli) undergoes a slight rotation away from 5 
A2451 for H. marismortui (2486 for E.coli), and the base of A2453 for H. marismortui (2488 for 
E. coli) rotates by approximately 40 ° about its glycosidic bond. This rotation allows A2453 for 
H. marismortui (2488 for E. coli) to form a base pair with U2500 H. marismortui (2535 for E. 
coli) and improves its stacking on C2452 for H. marismortui (2487 for E. coli).176 
One of the main actions of HHT (2) is induction of apoptosis (Figure 25). HHT (2) has a 10 
different mechanism of action from that of tyrosine kinase inhibitors, a class of drugs used in for 
the treatement of chronic myloid leukemia (CML). Accordingly its activity in CML is 
independent of the mutation state of BCR-ABL cells (particular CML cells that contain a fusion 
gene called BCR-ABL1, generated by translocation of sequences from the c-ABLgene on 
chromosome 9 into the BCR gene on chromosome 22).179 15 
The mechanism of apoptosis induced by HHT (2) was studied on different leukemic cell lines: 
U937, HL-60, HL60/MRP, HEL, THP, K562, MUTZ-1, CD34+/38lo, CD34+, U-87MG, 
ΔEGFR, NB4, KU812, and KCL22 and on other diseases including systematic mastocytosis 
(SM) cell lines: HMC-1.2 and P815, multiple myeloma (MM) cell lines AMO-1, IM9, 
RPMI8226, EJM, U266, BA/F3, hematopoietic cell lines, OPM-2 and human hepatoma QGY-20 
7703 cells. 
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Figure 25: Interaction of HHT (2) with the ribosome of H. marismortui and the conformational 
changes associated with this binding. 
 
A study was conducted on SHI-1 cell lines to prove that mitochondria are involved in the 5 
apoptosis induced by HHT (2).180 Although HHT (2) induces apoptosis mediated by 
mitochondria (intrinsic pathway) it induces also apoptosis through death receptors (extrinsic 
pathway). The intrinsic pathway is induced by cleaving the pro-active forms into active ones. 
HHT (2) activates some apoptosis mediators; it inhibits the apoptotic inhibitors and upregulates 
the release of other mediators through the action on genetic level. For instance apoptosis was 10 
studied in QGY-7703 cell line and seventy-eight individual mRNAs were identified as having 
their transcription levels significantly changed. Those genes were mostly oncogenes, tumor 
suppressors, enzymes, kinases and partially related to apoptosis, 68% being upregulated and 32% 
were downregulated. The following signaling apoptosis pathways were activated: TGF-β, TNF, 
FAS, p38MAPK, and p53.181 The head protein of intrinsic apoptosis cascade is p53. It was 15 
activated by HHT (2) in human hepatoma QGY-7703 cells181 but cell line with p53 mutation was 
more resistant to HHT (2).182 A study demonstrated rapid apoptosis of U937 and HL60 cell lines 
upon treatment with HHT (2), this was measured by increased annexin V binding capacity, 
caspase-3 activation, and the cleavage of poly(ADP-ribose) polymerase (PARP). Also, the 
expression of Bax was upregulated during cell death induced by HHT (2), while the expression 20 
of bcl-2 was only slightly decreased.183 Upon treatment of human myelodysplastic syndrome 
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(MDS) MUTZ-1 cell lines with HHT (2), Ca2+ translocated from endoplasmic reticulum (ER) 
pool to cytosol, the mitochondrial membrane potential decreased and Bid protein translocated 
from ER to mitochondria. Ca2+ and Bid proteins were released from ER pool to cytosol. The 
activation of ER stress-associated pro-apoptotic factor, CHOP and ER chaperones BiP and XBP1 
genes, was followed by cleavage of caspase-3 but not caspase-4.184,185 5 
mRNA expression levels of survivin were investigated in various hematopoietic cell lines in 
relation with apoptosis induced by HHT (2). It was concluded that the apoptotic effect of HHT 
(2) on the hematopoietic cell lines is associated with decreased level of survivin expression.186 In 
a study of apoptosis using ssHHT (2) on HL60 and HL60/ MRP (cells lacking Baxes) cell lines, 
ssHHT (2) was effective in a time- and dose-dependent manner, and independently of the 10 
expression of Bax. Additionally, ssHHT (2) induced apoptosis through the decrease of 
mitochondrial membrane potential and the release of cytochrome c. This was explained by 
decreased myeloid cell leukemia-1 (Mcl-1) level and cleavage of Bcl-2, one of the proteins that 
governs the outer membrane of the mitochondria, and has anti-apoptotic activity (Figure 26).187 
HHT (2) inhibited the telomerase content of HL-60 cells effectively and induced apoptosis.188  15 
HHT (2) inhibits synthesis of anti-apoptotic proteins of the Bcl-2 family, including Mcl-1 cell 
lines, leading to cell death. HHT (2) effectively induced apoptosis in primary CML stem cells 
(CD34+/38lo) by downregulation of Mcl-1 protein.189  
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Figure 26: Main pathways involved in apoptosis mechanism induced by HHT (2). Yellow: 
apoptosis factor; Blue: apoptosis intermediator; Turquoise: Dual role as intermediator and factor; 
Green: Apoptosis inhibitor 
 5 
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The intrinsic apoptosis using transforming subfamily of growth factor-β-inducible Sp1-like 
proteins called transforming growth factor-beta inducible early protein gene (TIEG1) was 
studied. TIEG1 induced apoptosis through up-regulation of Bax and Bim and down-regulation of 
Bcl-2 and Bcl-XL, release of cytochrome c and caspase-3 activation.190 The apoptotic effect of 
HHT was studied in K562 cell line using gene chip technology, it was found that seventeen 5 
genes were up-regulated and twenty seven were down-regulated. Most of them were found to be 
related to apoptosis, oncogenes, or tumor suppression. Several genes with altered gene 
expression were found, such as TIEG, vitamin D3 upregulated protein 1 gene (VDUP1), RNA 
binding motif protein 4 gene (RBM4) and v-myc myelocytomatosis viral oncogene homolog (C-
MYC). The activated transforming growth factor-β and tumor necrosis factor signaling pathways 10 
play an important role in apoptosis according to the dynamic gene expression pattern in these 
apoptotic cells. TIEG was significantly modified after induction of apoptosis, which is critical 
for apoptosis signal transmission.191 A Chinese team tried to identify different genes whose 
expression is modified during apoptosis induced by HHT (2) on leukemic HL-60 cell lines; they 
demonstrated that TGF-α and TNF apoptosis signaling pathways were initiated but not the Fas 15 
signaling pathway. Overexpression of TIEG and VDUP1 could induce apoptosis in some kinds 
of cells and they were up-regulated. Other genes, such as BRD2, ACVRL1 and RBM4 were also 
up-regulated and are probably involved in apoptosis signaling pathways.192  
The efficacy of HHT (2) against ponatinib-resistant Ph-positive cells Ba/F3 (Ba/F3 ponatinib-R) 
was shown by decreased protein expression levels of BCR-ABL and Crk-L. On the other hand, 20 
caspase 3 and cleaved poly(adenosine 5’-diphosphate-ribose) polymerase (PARP) levels were 
significantly increased. HHT (2) treatment reduced the expression of BCR-ABL, as well as heat 
shock protein (HSP) 90, which stabilizes the BCR-ABL protein. It was found that HHT reduced 
the expression level of the anti-apoptotic protein Bcl-2 and of c-Myc. HHT (2) was examined on 
ponatinib-resistant primary Ph-positive ALL and chronic-phase CML cell lines. The synthesis of 25 
BCR-ABL, HSP90, and Bcl-2 was downregulated and was independent of caspase activity.193 
HHT (2) antagonizes specifically the p-eIF4F function which is specifically required by cancer 
cell for their survival and not the eIF4F which is required for normal cells.194 HHT (2) reduces 
the levels of pro-oncogenic or pro-survival proteins (important proteins for tumorigenesis) 
having short half-lives, like Mcl-1, cyclin D1 or c-Myc. This was demonstrated on a well-studied 30 
transgenic mice model Eµ-myc lymphomas harboring lesions in Pten, Tsc2, Bcl-2, or eIF4E.175  
Cytotoxicity of HHT (2) and cell growth activity were investigated in three acute myeloid 
lymphoma (AML) cell lines, HL-60, NB4, and U937, and in three CML cell lines, K562, 
KU812, and KCL22. AML cells showed more sensitivity than CML cells to HHT-induced 
cytotoxicity. Using HL-60 cells, it was revealed that HHT (2) decreased the levels of Mcl-1, X-35 
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linked inhibitor of apoptosis protein (XIAP), survivin, and B-cell lymphoma 2 (Bcl-2) homology 
domain 3 (BH3)-only proteins as well as the mitochondrial membrane potential (Dwm). U937, 
K562, KU812, and KCL22 cells that expressed B-cell lymphoma-extra-large (Bcl-xL) (anti-
apoptotic transmembrane protein in the mitochondria) were less responsive to HHT-induced 
apoptosis than HL-60 cells. It was suggested that Bcl-xL plays a more important role than Bcl-2 5 
and Mcl-1 in protecting against HHT (2)-induced apoptosis.195 
In addition, it was demonstrated in leukemic cell lines K562 that HHT (2) inhibits the synthesis 
of VEGF (vascular endothelial growth factor), an important mediator of angiogenesis in the bone 
marrow. This work thus demonstrated a possible anti-angiogenic activity for HHT (2).196 
A study to identify novel biomarker that might contribute to variation in response to HHT (2) by 10 
using a panel of various human lymphoblastoid cell lines was performed. Genome-wide 
association analysis was applied using single nucleotide polymorphism (SNP) and mRNA 
expression data. The integrated analysis identified four unique SNPs that were associated with 
both expression and area under the curve (AUC). Functional validation using siRNA knockdown 
in leukemia cell lines showed that knocking down CCDC88A, CTBP2, SOCS4 genes in U937 15 
and K562 cell lines significantly altered HHT (2) cytotoxicity.197 
The overexpression of EphB4 contributed to Imatinib (IM) resistance in CML line cells. Cell 
lines from a patient with relapsed CML were established at the time of first diagnosis and after 
being relapsed. EphB4/RhoA may be a new marker for IM resistance. This is supported by the 
fact that HHT (2) with IM yielded more treatment advantages than IM alone by blocking 20 
EphB4/RhoA pathways.198,199 
Apoptosis varying intervals in K562 cell line treated with HHT (2) was studied. The results 
showed that the viability of K562 cells reduced gradually from day 1 to day 5 and ascended from 
day 6 to day 8 after HHT (2) treatment. At the same time, the cleaved caspase-3 expression level 
in K562 cell lines increased gradually from day 1 to day 7, but decreased at the day 8 (P<0.05). 25 
From day 1 to day 8 after HHT (2) treatment, the BCL-2 expression level declined first and then 
went up (P<0.05). Autophagosome was also increased at day 8 after HHT (2) treatment. It is 
concluded that the apoptosis level of K562 cells after being treated with HHT (2) increased at the 
beginning of the treatment and then it declined, which may be associated by higher autophagy 
level in the late stage of HHT (2) treatment.200 A recent study demonstrated that HHT (2) binds 30 
to the DNA with an intercalation mode.201 Also, HHT (2) binds to the the telomere G-quadruplex 
which makes it a good model for drug design.202 
Analysis of proteins expression profiles in K562 cell line (a CML cell line) in response to HHT 
(2) treatment showed that nine proteins were down regulated and four up-regulated. Aside from 
alterations in apoptotic proteins and proteins associated with transcription and translation, 35 
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changes in oxidative stress response and redox reaction-related proteins, such as heat shock 
proteins (HSPs), DJ-1 and thioredoxin were revealed. Specifically, these proteins were decreased 
after HHT (2) treatment in K562 and primary CML cell lines.203 Also, it was found that HHT (2) 
is an effective inhibitor of unwanted angiogenesis.204,205 
6.1.2 Potential use for the treatment of other tumors 5 
Beside its use in the treatment of CML, HHT (2) is being investigated for other type of tumors 
alone and in combination with other drugs: HHT (2) significantly inhibited the proliferation of 
human MM cell lines and tumor cells from patients with relapsed refractory MM in a dose-
dependent manner. This apoptotic process was associated with the activation of caspase-8, 
caspase-9, caspase-3 and poly (ADP-ribose) polymerase PARP.206 The effect of HHT (2) was 10 
demonstrated on MM, on the following cell lines AMO-1, IM9, RPMI8226, EJM, U266, and 
OPM-2, HHT (2) significantly reduced Mcl-1, a crucial protein involved in myeloma cell 
survival, in all the myeloma cell lines that were examined. Also, HHT (2) reduced the levels of 
c-FLIPL/S, activated caspase-8, and induced active reduction of Bid. It follows that HHT-
induced apoptosis appears to be mediated via both intrinsic and extrinsic apoptosis pathways. 15 
The resultant imbalance between BH3-only proteins and Mcl-1 may be pivotal for apoptosis by 
HHT (2). Also, HHT (2) treatment resulted in reduced levels of b-catenin and XIAP proteins, 
which also contribute to disease progression and resistance to chemotherapy in MM. HHT (2) 
enhanced the effects of melphalan, bortezomib, and ABT-737 when given in combinations with 
these agents. These results suggest that HHT (2) could constitute an attractive option for MM 20 
treatment through its ability to simultaneously target multiple tumor-promoting molecules.207 
HHT (2) and Bortezomib synergistically inhibit SKM-1 myelodysplastic syndrome (MDS) cell 
proliferation and induce apoptosis in vitro.208  
Transmembrane receptor of the tyrosine kinase KIT oncoprotein is an important therapeutic 
target as part of the type III tyrosine kinases. Some mutations in this receptor (V560G, D816V or 25 
D814Y) give it the ability of auto-dimerisation and auto-phosphorylation without activation by 
its ligand, which can eventually lead to uncontrolled cell proliferation and a resistance to 
apoptosis. The gain of function associated with these mutations of the KIT receptor plays a 
critical role in the pathogenesis of systemic mastocytosis (SM) and gastrointestinal stromal 
tumors (GISTs). The hypothesis that HHT (2), as an inhibitor of protein synthesis, decreases the 30 
protein level of KIT thereby reduces the level of phospho-KIT and repeals its constitutive 
signaling downstream. HHT (2) is effective both in vitro and in vivo demonstrating that it 
effecitively inhibits tumor growth in mice and induced apoptosis of tumor cells carrying the 
V560G (sensitive to IM) and D816V (insensitive to IM) mutations of KIT. In addition, HHT (2) 
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significantly prolonged the mouse survival time with aggressive SM (35 days instead of 7) 
though a rapid resistance to HHT (2) was observed in this case.209 
Potential activity of HHT (2) against clear cell type renal cell carcinoma (RCC) with mutant von 
Hippel-Lindau (VHL) gene was revealed by high-throughput simultaneous screen and 
counterscreen.210 In addition, HHT (2) has the potential of treatment the Gefitinib-resistant non-5 
small cell lung cancer, according to an in vivo study.211 
6.1.3. Combination with other agents 
A signal oncogene is important for some tumors for their continued activity of their malignant 
phenotype. The BCR-ABL fusion protein in chronic myelogenous leukemia (CML) is the best-
studied example. HHT (2) that inhibits protein synthesis thus reduces the level of the BCR-ABL 10 
protein level. The kinase activity of BCR-ABL is directly inhibited by imatinib (IM) and 
flavopiridol (a transcription inhibitor). The median-effect method was used to evaluate 
combinations of flavopiridol/HHT (2) and flavopiridol/IM. The resulting analysis indicated 
synergistic decrease in the clonogenicity. Synergy increased when HHT (2) and IM were 
administered sequentially as opposed to simultaneously. Transfected IM-resistant Ba/F3 cells 15 
that expressed the E255K and T315I mutations of BCR-ABL were not cross-resistant to 
flavopiridol and HHT (2). These results provided a rationale for the combination of inhibitors of 
transcription and/or translation with specific kinase inhibitors.212 
The combination of HHT (2) and doxorubicin (DOX) had ratio-dependent synergistic activities, 
with very strong synergism observed at a molar ratio of 4/1 (DOX/HHT) within double-loaded 20 
liposomes. According to this study liposomal co-delivery of DOX and HHT (2) could 
synergistically potentiate antitumor effects 213  
HL60/ADR, Kasumi-1 and primary AML cells were pre-treated with Decitabine and then 
exposed to HAA regimen (HHT, aclarubicin and cytarabine). Decitabine increased cytotoxic 
effect of HAA regimen and enhanced apoptosis in chemoresistant AML cells.214 25 
A synergistic effect of Sulforaphane (SF) in human CML cell line K562 with chemotherapy 
drugs HHT (2) and cytosine arabinoside (Ara-c) was found and indicated clinical potential.215 
The combination of HHT (2) and YM155 was investigated on K562 cell lines and it was found 
to be synergistic. The mechanism was related to the apoptosis induced through downregulation 
of survivin.216  30 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic 
ligand from the TNF-α family. HHT (2) represents a very efficient enhancer of TRAIL-induced 
apoptosis with potential application in TRAIL-based, anticancer combination therapy. The 
agonistic anti-TRAIL receptor antibody is a potential anti-tumor agent. HHT (2) was found to be 
a very effective, (in nano-molar dose) enhancer of TRAIL-mediated apoptosis/growth 35 
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suppression. Co-treatment of TRAIL-resistant RKO or HT-29 cells with HHT (2) and TRAIL 
led to the effective induction of apoptosis and the complete elimination of the treated cells. HHT 
(2) suppressed the expression of the antiapoptotic proteins Mcl-1 and cFLIP and enhanced the 
TRAIL-triggered activation of JNK and p38 kinases.217 Another study suggested that HHT (2) 
can replace toxic substances such as cycloheximide because it activates necroptosis through the 5 
same signaling pathways (involving RIPK1/RIPK3/MLKL) to sensitize human cancer cells to 
TRAIL-induced necroptosis.218  
HHT (2) was combined with antiproliferatives such as alkylating agents, intercalating agents, 
metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic 
acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic 10 
enzymes, for the treatment of a host with a cellular proliferative disease, particularly a 
neoplasia.219 When matrine combined with HHT (2) was tested on the proliferation of human 
AML cells HL-60, a synergistic effect on apoptosis was noticed.220 221  
6.1.4 Resistance mechanism for HHT 
The main mechanism of HHT (2) resistance is through a pump that removes HHT (2) from 15 
tumor cells. This transporter is called drug-efflux pump P-glycoprotein, also known as MDR1. 
Through the action of this pump the intracellular drug levels may remain sub-lethal and, in the 
case of upregulation of MDR1, cancer cells may survive. The HHT-resistant cell line SKM-
1/HHT was established and the prominent overexpression of MRD1 may be the main cause for 
multidrug resistance.222 ssHHT (2) derivatives that bypass MDR1 might improve treatment 20 
efficacy. 
Short hairpin RNAs (shRNAs) were designed, constructed and transfected into HT9 leukemia 
cell line, for specific silencing of the MRD1 gene. Resistance against HT (3), doxorubicin and 
curcumin was decreased alongside the decreased expression of MRD1. The study indicated that 
shRNA recombinant plasmids could modulate MDR in vitro.223 25 
Human multi-drug resistance (MDR) B-cell lymphoma cell line BJAB/ADR was found to be 
resistant to HHT (2), daunorubicin (DNR), etoposide and mitoxantrone (MTX).224 
A study on the pharmacological effect of HHT (2) on the molecular level was conducted. CET 
(1) and HHT (2) were tested for resistance on the MDR cell lines. These were the 55 cell lines of 
the Developmental Therapeutics Program of the National Cancer Institute (NCI, Bethesda, Md., 30 
USA) that over express the conferring P-glycoprotein/MDR1 (CEM/ADR5000), that can expel 
HHT (2) of the cell and consequently which can attenuate its activity. In CEM/ADR5000 cells, a 
threefold increase to HHT (2) resistance was observed, though the other MDR cell lines did not 
show cross-resistance.225 
6.1.5 Mechanism of allergic reaction  35 
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HHT (2) was screened and identified as a potential allergic factor. Histamine 1 receptor/cell 
membrane chromatography (H1R/CMC) model was applied for capturing membrane retained 
components which could induce H1R activation. Retention components were enriched and 
analyzed by H1R/CMC-HPLC/MS. HHT (2) was recognized, separated and identified in HHT 
(2) medication. Ca2+ flux assay and p-IP3R (channels that most often mediate Ca2+ release from 5 
intracellular stores) expression found that HHT (2) retained by the H1R/CMC model increased 
phosphorylation of IP3R and promoted cytosolic free Ca2+ elevation in a dose-dependent manner 
which further verified the activity of HHT (2) in activating H1R. This provides an indication that 
a patient with over-expressed H1R should be aware of possible allergic reaction when applying 
HHT (2) injection.226  10 
6.1.6 Other Pharmacological applications 
From the the chloroform extract of the aerial parts of the only Cephalotaxus harringtonia L. 
specimen grown in Egypt, five known alkaloids CET (1), HHT (2), HT (3), isoHT (4) and 
deoxyHT (5) were identified by HPLC–ESI–MS.227 This extract was tested in vitro for its 
cytotoxicity against HCT116, HepG2 and MCF-7 cell lines and resulted with IC50 values of 4.77, 15 
12.9 and 17.5 μg/ml, while doxorubicine had IC50 values of 3.74, 4.57 and 2.97 μg/ml against 
these cell lines, respectively. 
Chikungunya virus (CHIKV) is a mosquito-transmitted virus that has reemerged as a significant 
public health threat in the last decade. HT (3) displayed potent inhibition of CHIKV infection 
(EC50 0.24 µM) with minimal cytotoxicity. HT (3) acts on the post-entry stage of the CHIKV 20 
replication cycle and strongly interferes with the process of viral protein synthesis.228 
Cryptosporidium parasites cause cryptosporidiosis, a diarrheal disease usually, can result in 
fulminant diarrhea and death in AIDS patients and chronic infection and stunting in children. A 
library of drug repurposing candidates were screened against Cryptosporidium parvum among 
which HHT (2) showed promising in vitro activity, its IC50 activity was 0.86 µM.
229  25 
HHT (2) and CET (2) were tested against the hepatitis B virus (HCV), using the bovine viral 
diarrhoea virus (BVDV) as surrogate for HCV. The activity relative to BVDV was determined 
by reduction of BVDV-RNA production and protection of infected embryonic bovine trachea 
(EBTr) cells. Activity against HBV was investigated by HBsAg release and HBV-DNA release 
from hepatoblastoma HepG2 2.2.15 cells infected with HBV. HHT showed high activity against 30 
HBV (IC50 was 2 ϻM against HBV but it has a very low therapeutic index).230 CET (1) and HHT 
(2) induced toxicity in EBTr cells and had no protective effect against BVDV. In contrast, they 
were able to inhibit HBV production at concentrations 10- to 100-fold lower than other 
molecules inducing cell toxicity, which suggests that they are potentially useful in combined 
therapy against hepatitis B. 35 
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A library of two hundred and ninety compounds was screened for antiviral activity against 
Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory 
syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was 
dependent on current or previous FDA approval or advanced clinical development. Some drugs 
that had a well-defined cellular pathway as targets were included. In total, 27 compounds with 5 
activity against both MERS-CoV and SARS-CoV were identified. The EC50 activity of HHT (2) 
against MERS-CoV was 71.8 nM.231 
HT (3) was extremely effective in inhibiting human retinal glial cell proliferation. Its activity 
was comparable to other antiproliferative drugs such as colchicine, daunomycin and 5-
fluorouracil. HT (3) is therefore a potential drug for the treatment of proliferative 10 
vitreoretinopathy (PVR).232  
In 2009, the inhibitory effects of HHT (2) on CML and B-ALL (B cell acute lymphoblastic 
leukemia) cell line was evaluated in vitro and showed that over 90 % of leukemic stem cells 
were killed after treatment with HHT (2). In contrast, less than 9 or 25% of leukemic stem cells 
were killed after treatment with IM or dasatinib, respectively.233 15 
HHT (2) has demonstrated activity against coronavirus with an IC50 ranging from 11 nM to 1.2 
µM.234 Also, HHT (2) when combined with the saponin digitonin showed activity against 
Trypanosoma brucei brucei.235 
 
6.2 Clinical application 20 
HHT (2) or Omacetaxine mepesuccinate (International nonproprietary name (INN)) (OM) 
provides a treatment option with a distinct mechanism of action for patients who have not 
achieved an optimal outcome with TKIs, including patients with the T315I mutation.236 Recent 
reviews compiled clinical trials conducted first in China with mixtures of HHT (2) and HT (3), 
then in Western countries using purified high purity ssHHT (2) reported in 1998 by Robin 25 
(OncoPharm founder) also known as omacetaxine mepesuccinate allowing to confirm its 
efficacy in CML and put the first EMA application in 2004 leading to its orphan drug status in 
2009, and in the US with a stable source of hydrosoluble omacetaxine reported in 2001 by 
Brown (ChemGenex founder).12,237,238,239,240 
6.2.1 Approved clinical applications 30 
HHT (2) was approved in 2009 by the European medicine agency (EMA) for t-Philadelphia 
chromosome positive chronic myeloid leukaemia in patients who have the T315I BCR-ABL 
kinase domain mutation and who are resistant to prior IM therapy.241 It was approved by the 
FDA in October 2012 for the treatment of CML in chronic or accelerated phase after failure of 
two or more TKIs.242 35 
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6.2.2 Different clinical trials for chronic myeloid leukemia 
To evaluate the pharmacokinetics of HHT (2), sensitive high-performance liquid 
chromatography (HPLC)-tandem mass spectrometry (LC-MS/MS) assays for the quantification 
of omacetaxine and its inactive 4′-desmethyl (4′-DMHHT) and cephalotaxine metabolites in 
human plasma and urine were developed and validated, according to the latest FDA and EMA 5 
guidelines.243 Deuterated isotopes were used as internal standards and these assays were 
considered very suitable to support clinical pharmacologic studies of omacetaxine 
mepesuccinate. Since omacetaxine is mainly metabolized by esterases, the plasma samples were 
immediately stabilized after collection with an esterase inhibitor and stored at a nominal 
temperature of -80 °C. The validated plasma assay quantifies all analytes in the concentration 10 
range of 0.1-100 ng/mL and the urine assay in the range of 0.1-50 ng/mL. At all concentrations, 
the accuracies were within ±15% of the nominal concentrations and precisions were ≤15%. The 
developed methods have successfully been applied in a human mass balance study of 
omacetaxine. 
Nearly 70% to 90% of patients with CML in the early chronic phase who were treated with IM 15 
achieved complete cytogenetic response. With a median follow-up period of 5 years, the annual 
rate of resistance or progression is 3% to 4%, and the mortality is 1% to 2%.244 
In 2001 a study was conducted on 37 patients ≤ 21 years old with recurrent refractory AML, 
twenty-eight patients were evaluable for response. Four patients responded completely and one 
responded partially (response rate 5/28 18%) the median duration was roughly 62 days. This 20 
study showed potential use of HHT (2) for pediatrics with tolerable toxicity.245 
Two cases of CML patients acquired the T315I mutation after IM treatment; one was treated 
with recombinant interferon-alpha (IFN-α), and the patient was in complete hematologic 
remission (CHR) ten months later, while the other patient treated with HHT (2) started at 1.25 
mg/m2 subcutaneously twice daily for 5 consecutive days every month achieved a CHR after five 25 
months.246 
The outcomes of one hundred seventy six patients of accelerated-phase CML who received 
treatment with imatinib were reviewed and compared with the outcomes of 213 historic control 
patients treated with other drugs including HHT (2). Treatments included INF-α (hundred 
patients), HHT (2) (thirty five patients), DNR plus cytarabine (twenty three patients), decitabine 30 
(forty seven patients), and other therapies (eight patients). Complete hematologic responses were 
82% with IM and 35% with HHT (2).247  
In 2010, eight TKI-resistant chronic-phase CML patients unmutated and T315I-mutated BCR-
ABL were enrolled in a clinical trial. They all received HHT (2) to investigate if patients will be 
re-sensitized to TKIs. Initially a rapid decline and a sustained disappearance of T315I-mutated 35 
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transcripts were observed in 50% of patients. This result indicates the disappearance of the 
mutated clone.248 
In 2009, a year-long study on long term treatment with HHT (2) was carried out. A year-long 
study on long term treatment with HHT (2) was carried out. One hundred six patients with CML 
received 1.5 mg/m2 of HHT (2) alone for seven to nine days every four weeks. Seventy nine 5 
patients were in the control group, thirty one were treated with interferon alpha (IFN-α) and forty 
eight with hydroxycarbamide. Seventeen patients who were treated with IFN-α failed to achieve 
cytogenetic response within twelve months and subsequently received HHT (2) as a salvage 
treatment. After twelve months of therapy, cytogenetic response rate of the HHT (2), IFN-α and 
hydroxycarbamide groups were 39/106, 14/31 and 3/48, and corresponding molecular 10 
cytogenetic response rates 6/18, 3/8 and 0, respectively. Of the seventeen patients who received 
HHT (2) as salvage treatment, six achieved cytogenetic response (3 major). At the forty eight 
months' follow-up, cytogenetic response was maintained in 32/39 patients treated with HHT (2). 
Patients who had cytogenetic response in HHT (2) group or treated with IFN-α also showed 
longer median chronic durations, which were 45 months (12 months-98 months) and forty nine 15 
months (12 months-92 months) respectively, indicating a longer survival time.249 
In 2015, the efficacy and safety data of long-term administration of HHT (2) were evaluated. 
After 24 months of follow-up, the final analysis included additional efficacy and safety analyses 
to assess the benefit of long-term HHT (2) administration (1.25 mg/m2 twice daily for fourteen 
days every twenty eight days followed by seven days every twenty eight days) in chronic phase 20 
(CP) and accelerated phase (AP) CML patients who received >3 cycles. 18% of CP-CML 
patients achieved a major cytogenetic response (MCyR) with a median duration of 12.5 months. 
Responses were maintained for twelve months in three of forteen responders, and the median 
overall survival (OS) was 40.3 months. Among patients with AP-CML, 14% achieved or 
maintained a major hematologic response for a median of 4.7 months, MCyR was not achieved, 25 
and the median OS was 14.3 months. In patients with CP-CML and patients with AP-CML who 
received >3 cycles of treatment (n-50 and n-14, respectively), the median OS was 49.3 and 24.6 
months respectively. Grade 3 or higher hematologic toxicities were the major side effects (79% 
and 73% for CP-CML and AP-CML, respectively), with discontinuation due to toxicity in 10% 
of CP patients and in 5% of AP patients.250  30 
The efficacy and safety of HHT (2) in patients with AP-CML previously treated with tyrosine 
kinase inhibitors were assessed in two phase II trials. Fifty-one patients in AP-CML and forty 
four in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice 
daily days 1-14 every 28 days until hematologic response/improvement or any cytogenetic 
response, then days 1-7 every 28 days until disease progression. A major hematologic response 35 
 133 
(MHR) was 37% in patients with AP-CML and 9% in patients with BP-CML (22% and 5% in 
those were with a history of T315I mutation).251 
In 2007, a 63 old male CML patient was reported harboring a T315I BCR-ABL mutation while 
on IM treatment that completely disappeared when he was treated with HHT (2).252 
In 2013, HHT (2) produced good clinical responses with acceptable tolerance levels in patients 5 
with CML-chronic phase (CP) who had been treated with 2 or more TKIs. This Data was 
analyzed from two phase II clinical trials of eighty one patients with CML-CPs. The median age 
of those in the analysis was 59 years (range, 26-83 years). Eight patients completely responded. 
The median duration for the study was 17.7 months. Fifty-six patients (69%) achieved and/or 
maintained hematologic response for at least eight weeks. The overall survival was 34 months.253 10 
In 2015, a study was carried on thirty one CML patients with complete cytogenic response to 
compare the immunological effect on T lymphocytes between HHT (2) (fifteen patients) and IM 
(sixteen patients), the study indicated that both have the same effect.254 
6.2.3 Administration, dosage, metabolites and elimination 
A recent review discussed the use and effectiveness of HHT (2) in the treatment of intractable 15 
CML, with coverage of its pharmacology, mode of action, and pharmacokinetics.237 A 
subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials. HHT (2) at 
1.25 mg/m2 SC was administered (twice daily) BID, days 1-14 every 28 days for two cycles. 
This mode of administration was developed because in early clinical studies short intravenous 
(IV) infusions (over 60-90 min) was used but life-threatening hypotension and tachycardia were 20 
observed at dose levels above 3-4 mg/m2.255 A stable aqueous solution for injection of HHT (2) 
was prepared with tartaric acid at pH around 4.256 It is only recently however that the site of 
protonation, although obvious, was unambiguously seen at N9 of CET (1) or HT (3) as 
established through X-Ray diffraction studies of various organic salts,76 an observation in 
concordance with Steitz176 (see Figure 25) and Takano’s60 results implying that N9 should be 25 
available for protonation to ensure its biological activity. Therefore, harringtonines seem to be 
active via their protonated form. The maximum tolerated dose was estimated to be 5 mg/m2.257 It 
is provided in vials that contain 3.5 mg HHT (2) as a sterile, preservative-free and white to off-
white lyophilized single-use solution for injection.241 In a recent patent HHT (2) was 
incorporated in phycobniliprotein nanoparticles.258 HHT (2) can be given as aqueous solution 30 
preferably at a pH of about 4. Also it can be provided orally.259,260,261,262,263 The protonated form 
of HHT (2) was patented for potential application in oral and intravenous dosage forms.264 
MM remains an incurable disease in most patients. Newly developed high proportion 
polyethyleneglycol (H-PEG) of long-circulating liposomes (LCL) loaded with HHT (2) (HHT-
LCL-H-PEG) may be regarded as a promising nano-device to deliver anti-MM drug HHT (2) for 35 
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treatment of MM patients.265 This HHT-LCL freeze-dried powder can significantly improve 
storage stability, can make HHT-LCL freeze-dried powder convenient to dilution administration, 
make drug in liposome sustained release, and extend the circulation time in blood, to improve the 
utilization rate of medicament effective component, and reduce toxic and side effects. 
The major metabolites of HHT (2) are CET (1) and 4’-desmethylHHT (31), they are detected by 5 
HPLC.266 In another study using 14C HHT and detection by High-performance liquid 
chromatography mass spectrometry (MS) (high resolution) in combination with off-line 
radioactivity determination, six metabolites were detected in the plasma, urine and feces, 
unchanged HHT (2) was predominant. 267,268 
6.2.4 Combination therapy 10 
Trials have been carried on combining HHT (2) with other anticancer drugs in order to synergize 
and potentiate the activities of these drugs and improve therapy outcome. In some cases, the 
associated drugs can be efficiently co-delivered in the form of liposomes.269  
6.2.4.1 Combination therapy for treatment chronic myeloid leukemia (CML) 
In 2002, the efficacy and safety of a combination regimen of simultaneous HHT (2), and IFN-15 
therapy was proved with thirty seven patients with CP-CML who were not treated previously by 
either agent. The complete hematologic response (CHR) rate was 85%.270 
In 2009, a clinical trial phase II carried on forty four previously untreated patients with 
Philadephia-positive chromosome (Ph+) CP-CML, the treatment consisted of HHT (2) (2.5 
mg/m2 per day) and cytarabine (7.5 mg/m2 per day). Both drugs were given together via 20 
continuous intravenous infusion for seven days. Thirty six of forty four patients (82%) achieved 
a complete hematologic remission. Although HHT/cytarabine was generally well tolerated, no 
significant amelioration as compared to interferon-refractory CML and was not nearly as high as 
association with IM in newly diagnosed patients.271  
In 2010 in China, twelve patients with CML in blast crisis who have failed prior single-agent 25 
therapy with IM were enrolled in clinical trial to investigate the induction therapy of granulocyte 
colony-stimulating factor (G-CSF) and low-dose HHT (2) as well as standard-dose IM (GHI). 
The outcome of this study suggested that the GHI regimen may overcome disease-poor response 
to conventional doses of IM followed by allogeneic hematopoietic stem cell transplantation 
(allo-HSCT).272 30 
Ninety patients with Ph+ CML in early chronic phase received the triple regimen IFN-α, ara-C, 
and HHT. After a median duration of 16.5 months of therapy, seventy-eight patients had their 
therapy changed to IM, eighty five patients (94%) achieved complete hematologic response and 
sixty seven patients (74%) had a cytogenetic response (Ph suppression to ≤ 90%).273 
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Fourteen patients were treated with a regimen that combines HHT (2) and IM among which six 
cases failed and eight cases sub-optimally responded to IM therapy. This trial proved the efficacy 
and safety of combining both drugs.274  
6.2.4.2 Combination therapy for treatment acute myeloid leukemia (AML) 
In 2009, eighty-seven AML patients were treated with HHT (2), cytarabine (Ara-C) and DNR 5 
(HAD) regimen, the complete remission rate of the eighty-seven cases was eighty/eighty-seven 
(92%).275 
Six hundred and twenty three newly diagnosed Chinese patients with AML were treated with 
induction chemotherapeutic regimens based on idarubicin, DNR and HHT (2). Total complete 
remission rate was 66.5%, median survival was eighteen months and estimated survival at three 10 
years was 30.8%. The third year relapse rate was 55.1%.276 
A group of two hundred and fifty four Chinese patients with de novo AML with glutathione S-
transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1) mutations were 
administered in a clinical study. As induction therapy, the patients were treated with HHT (2) 2.5 
mg/m2 intravenously on days 1-7, Ara-C 150 mg/m2/d continuous infusion on days 1-7, and 15 
DNR 45 mg/m2 intravenously on days 1-3 (HAD regimen). The second course of HAD induction 
therapy was applied to patients who were not in complete remission after the initial course of 
induction therapy. Post remission therapy consisted of HA regimen (HHT (2) and Ara-C) (course 
1 and 4), DA regimen (DNR and Ara-c) (courses 2 and 5), and MA regimen (MTX and Ara-c) or 
HAM (Ara-c days 1–4, combined with MTZ 8 mg/m2, intravenously on days 5-7) (courses 3 and 20 
6). Overall survival and disease-free survival of complete remission patients in GSTT1 and 
GSTM1 double present group was better than in GSTT1- and/or GSTM1-group.277  
A regimen was investigated to explore the effect of low dose of HHT (2) and Ara-C combined 
with granulocyte colony-stimulating factor (G-CSF) on patients with relapsed or refractory 
AML: thirty five out of sixty seven (52.2%) patients achieved complete remission and eight out 25 
of sixty seven (11.9%) achieved partial remission. The overall response rate was 64.1%.278 
In 2003 a clinical trial of combined regiments HHT (2), Ara-C and etoposide (VP-16) was 
conducted on twelve pediatric patients, nine patients achieved complete remission within 20–45 
days after one course of therapy. One patient had partial remission this clinical trial gave good 
indication for this combination.279 30 
HAA regimen (HHT (2), Ara-C and aclarubicin), was evaluated in forty six patients with 
refractory and/or relapsed AML for efficacy and toxicity. 80% of patients achieved complete 
remission.280  
β-Elemene emulsion had a curative effect in treatment of refractory/relapsed AML in 
combination with HAA regimen. This was clinically proven by comparing two groups one using 35 
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the HAA alone and one using β-elemene emulsion with HAA. The total effective rate in the β-
elemene emulsion plus HAA group was 80.8%. However, the total effective rate in the HAA 
only group was 52.9%.281 
Sixty-seven patients with relapsed or refractory AML were enrolled in a clinical trial. They 
received the following treatment: HHT (2), cytarabine (Ara-C) and granulocyte colony-5 
stimulating factor (G-CSF) (HAG). All the patients were treated with HAG regimen. Thirty five 
patients (52.2%) achieved complete remission and eight (11.9%) partial remission. The overall 
response rate was 64.1%282  
One hundred and ninety six untreated de novo AML patients were recruited in China for a 
clinical trial using HHT (2). Patients were treated with HHT (2) and cytosine arabinoside (HA) 10 
based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-DNR, M-
MTX). The complete response rate was one hundred and fifty three of all cases (78.1%).283  
One hundred and seventy-one pediatric patients were recruited in a trial. They received a 
regimen including HHT cytarabine and DNR with a median age of 7.58 years, Complete 
response was obtained in one hundred forty of hundred and seventy-one (81.9%) cases within 15 
sixty days. The 5-year event-free survival was 52.75%.284 
Fourty eight patients median aged thirty five (14–57) years were enrolled into a clinical study to 
evaluate the efficacy and toxicity of HAA regimen (HHT (2), Ara-C (cytarabine), aclarubicin) as 
an induction therapy in the treatment of de novo AML. The HAA regimen was a well-tolerable 
and effective induction regimen for patients with de novo AML.285  20 
A case was reported with primary refractory FLT3-ITD-positive AML was treated with 
combination of low dose HHT (2) and Sorafenib (salvage treatment); the therapy was successful 
and the patient was in complete remission.286  
Ninety elderly patients with AML were chosen and divided into CAG (low-dose cytarabine and 
aclarubicin in combination with G-CSF) group (fifty two cases) and HAG (HHT (2) and 25 
cytarabine (Ara-C) combined with G-CSF) group (thirty eight cases). In the CAG group were 
thirty eight cases with complete remission (73.08%) and total efficiency was 84.62%; forty cases 
with complete remission in HAG group (36.84%) and total efficiency was 73.68% in the HAG 
group. CAG regimen was more efficient than HAG in elderly patients with AML.287 
In a recent clinical study for elderly patients with de novo AML, 56 patients were enrolled in this 30 
study. They were treated with HHT (2) and cytarabine in combination with G-CSF (HAG). Up 
dated results showed good overall survival.288 
A recent meta-analysis provided an overview of the effectiveness of HHT (2) combination 
regimens to treat AML. Twenty one studies were analyzed including one thousand three hundred 
and ten patients, two hundred twenty nine pediatric, and two hundred sixteen elderly. HHT (2) 35 
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was given in combination with cytarabine, DNR, idarubicin, aclacinomycin, MTX or G-CSF. 
This retroanalysis showed the superiority of HHT (2)-containing regimens in AML treatments. 
6.2.5 Other Clinical applications 
Clearly, other potential clinical applications are the other subtype of leukemia. Consequently 
different clinical trials with different regiments took place: 5 
Thirty one adult patients suffering from idiopathic thrombocytopenic purpura (ITP) were treated 
with low-dose combination chemotherapy consisting of cyclophosphamide and prednisone on 
days 1 to 7, combined with vincrinstine on day 1, and/or azathioprine on days 1 to 5 or 7 and/or 
HHT (2) on days 1, 3, 5 or on days 1–7 and/or etoposide on days 1 to 7.289 The output was as 
following: thirteen of thirty one (41.9%) patients had complete remission, nine (29.0%) had 10 
partial remission and nine (29.0%) had no response. 
A forty-five year old female patient was reported with de novo acute megakaryoblastic leukemia 
(AMKL) (rare type of AML) with BCR/ABL rearrangement and der(16)t(1;16)(q21;q23) 
translocation but negative for t(9;22) Ph chromosome. Upon HAD induction chemotherapy, the 
patient achieved partial hematological remission. The patient was then switched to Imatinib (IM) 15 
plus one cycle of CAG regimen (low-dose cytarabine and aclarubicin in combination with G-
CSF). She achieved complete remission, the disease recurred after forty days and the patient 
eventually died of infection.290  
Thirty four myelodysplastic syndromes patients with MDS-RAEB and RAEB-T were recruited 
for a clinical trial of two regimens therapy of either HHT, cytarabine and aclarubicin (HAA) 20 
regimen, or Idarubicin Ara-C (IA) regimen. It was suggested that the HAA regimen is more 
effective than IA and well tolerated.291 
Thirty-three elderly patients were enrolled in a clinical trial, twenty-one patients with high-risk 
MDS and twelve with MDS–AML to evaluate the efficacy and toxicity of CHG induction 
chemotherapy (low-dose cytarabine, HHT (2) with G-CSF priming) for elderly patients with 25 
high-risk MDS or AML transformed from MDS (MDS–AML). As outcome of this study the 
overall response rate was 66.7% after one course of the CHG regimen with nineteen patients 
achieved complete remission (57.6%) and three patients achieved partial remission (9.1%).292 
In a long trial of nine years, fifty-three patients were enrolled to evaluate the effect of 
combination therapy of HHT (2) plus all-trans-retinoic acid (ATRA)-based therapy for the 30 
treatment of acute promyelocytic leukemia (APL) as induction therapy followed by three courses 
of consolidation chemotherapy and 2 years sequential therapy. All patients achieved complete 
remission.293  
A retrospective study on high risk one hundred and thirty-two patients with higher risk 
myelodysplastic syndrome (MDS) was done to compare two treatment combination therapy of 35 
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low-dose CHG (cytarabine, HHT (2) and G-CSF) and Decitabine. Complete remission was not 
significantly different between the groups (27.1% with Decitabine vs. 30.6% with CHG).294 
In a clinical study of total of ninety-eight patients at the acute phase of CML with invasive 
pulmonary aspergillosis (IPA) were treated with Voriconazole plus a low-dose of HHT (2) and 
IM. This study suggested that this combination could be used as the first-line therapy for IPA 5 
patients with CML.295 The forty-nine cases in observation group were treated with the 
combination while the control group was treated with fluconazole, low-dose of HHT (2) and IM. 
The effective rates of the observation group and the control group were 95.92% and 91.84%, 
respectively with no significant differences. The study concluded that Voriconazole and low-
dose HHT (2) and IM could be used as the first-line antifungals for the treatment of IPA patients 10 
with CML. 
Thirty-three patients were enrolled in a clinical study to investigate the effectiveness of HHT (2) 
and Cytarabine regimen for CML-MBC, overall improvement cytogenetic response was 60.1%, 
seven patients (21.2%) had partial response. The study concluded that it is an effective treatment 
and that CD34+CD7+ cells may be one of the valuable clinical parameters to assess treatment 15 
effectiveness.296 
6.2.6 Side effects 
The major side effect is myelosuppression (a condition in which bone marrow activity is 
decreased, resulting in fewer red blood cells, white blood cells, and platelets. Myelosuppression 
is a side effect of some cancer treatments),257,271,272,279 with gastrointestinal manifestation 20 
including diarrhea occurring as well in some cases.252  Those side effects were explained due to 
the effect of HHT (2) on the epithelial permeability of intestinal Caco-2 cell monolayers.297 
6.3 Natural extracts from Cephalotaxus sp. and natural Chinese medicine  
The essential oil of Cephalotaxus griffithii inhibited proliferation and migration of human 
cervical cancer cells.298 The oil from Cephalotaxus griffithii needle (CGN) extracted with 25 
petroleum ether was tested for its effect on proliferation of cancer cells (MTT assay on HeLa, 
ZR751 and HepG2 cell lines). The extract showed important phyto-components with multiple 
cellular targets for control of breast cancer.299  
Patents based on Chinese traditional medicine were filed containing Cephalotaxus as an 
ingredient combined with different plants’ extracts and are used for the following indication: 30 
treatment of phlegm stagnation type osteoarthritis,300 liver cancer,301 ischemic intestinal colic,302 
for phthisis,303 hepatitis syndrome,304 for leukemia,305 traumatic bleeding consists,306 hookworm 
disease,307 ovarian cancer,308,309 lump resolving agent in gastric cancer,310 treatment of gastric 
cancer,311 liver cancer,312 collateral cancer,313 rectal cancer,314,315 phlegm and fluid-retention 
lung-obstructing type cardiac insufficiency,316 treating liver-depression qi-stagnation type breast 35 
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cancer,317spleen-kidney-qi-deficiency bladder cancer,318 lung cancer.319 A preparation that 
inhibits the adhesion and migration of breast cancer, colorectal cancer, prostate cancer, lung 
cancer, gastric cancer, osteosarcoma and other cancer cells,320 liver fats.321 (Table 20). 
 
 5 
 
A patent for dermatological application reported that HHT (2) was an active inhibitor of matrix 
metalloproteinase-1 that can be used for reduction and prevention of wrinkles.322 Another 
preparation relates to a veterinary drug for treatment of bovine mastitis.323 Eventually, patents 
were filed using preparations that contain HHT (2) for treatment of water and purifying it from 10 
cyanobacteria.324 325 
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